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CHAPTER I 
Introduction 
  
1.1 Toxoplasma gondii as a Genetic Model System 
 
Toxoplasma gondii is a very successful protozoan parasite, infecting more than one 
third of the world’s population. Since its discovery in 1908 (Nicolle and Manceaux, 
1908; Splendore, 1908), it has been highly implicated in the pathogenesis of 
congenital neurological defects in developing fetuses and encephalitis among the 
immunocompromised individuals (Luft and Remington, 1992; Montoya and Rosso, 
2005). Toxoplasma belongs to the phylum Apicomplexa including other important 
human and veterinary pathogens: Plasmodium, the causative agent of malaria; Babesia, 
Eimeria and Cryptosporidium, the enteric pathogens; and Neospora and Theileria, the 
systemic veterinary pathogens (Kim and Weiss, 2004).  
 
Among these apicomplexan parasites, Toxoplasma is much easier to handle for genetic 
manipulation. Experimental techniques for both classical forward and reverse genetics 
have been well established over the past decades (Kim and Weiss, 2004). Moreover, 
Toxoplasma can be cultivated both in vitro and in mouse animal models without great 
difficulty. Thereby, it stands out as a very useful tool for studying the cell biology of 
the apicomplexan parasites. Herein, the detailed genetic manipulation approaches 
involved in the establishment of transgenic parasites and mutants will be delineated. 
 
1.1.1 The Establishment of Transgenic Parasites 
 
In order to successfully manipulate the Toxoplasma genome, several criteria need to 
take into consideration, including the efficiency of DNA transfection, the suitability of 
the selectable markers, and the relevance of the promoters used for the constructs. 
 
T. gondii was the first apicomplexan parasite to be successfully transfected (Donald 
and Roos, 1993; Kim et al., 1993; Soldati and Boothroyd, 1993). The remarkably high 
transfection efficiency allows T. gondii to be developed as an attractive tool for gene 
expression. Since then, an increasing number of heterologous reporter transgenes has 
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been generated. These reporters include green fluorescent protein (GFP), epitope 
tagging, and enzymes such as chloramphenicol acetyl transferase (CAT) and β-
galactosidase (LacZ) (Table 1.1; Gubbels et al., 2007). The expansion of this 
application on T. gondii has advanced our knowledge in understanding the parasite’s 
intracellular development, protein trafficking and organellar targeting.  
 
Beyond the transfection efficiency, the suitability of the selectable markers is another 
key consideration. Typically a plasmid DNA harbors two expression cassettes. The 
first one encodes the target gene and the second one is with the selectable marker 
(Striepen and Soldati, 2007). After electroporation, the plasmid DNA is introduced 
into the parasites, mainly tachyzoites, and the expression of the selectable marker 
subsequently enables the transformants to be selected. A wide variety of selection 
markers is available to T. gondii, such as CAT, dihydrogolate reductase-thymidylate 
synthase (DHFR-TS), and hypoxanthine- xanthine-guanine phosphoribosyl transferase 
(HXGPRT). The drug selection is very specific for the parasites, normally without 
causing substantial toxicity to the host cells. Hence, the establishment of a stable 
transgenic line is reasonably successful and efficient in Toxoplasma.  
 
Transcription in Toxoplasma is monocistronic in nature and the transcription 
efficiency depends on the promoter elements that are closely in the proximity to the 
transcription start site (Striepen and Soldati, 2007). The choice of a suitable promoter 
for the expression vector is very critical since it affects the timing and the expression 
of the transgenes (Gubbels et al., 2007). Despite these concerns, it is generally not an 
obstacle to transgenes establishment. Both constitutive and regulatable promoters were 
designed for Toxoplasma expression vector, which may be different in transcription 
strength and can be stage-specific. The commonly used constitutive promoters are 
derived from α-tubulin (TUB1), DHFR, several dense-granule proteins (GRAs), 
rhoptry protein 1 (ROP1), and microneme protein 2 (MIC2). The GRAs and MIC2 
promoters are the strongest promoters and the DHFR promoter is the weakest one. All 
these promoters are specific for the tachyzoite stage while the bradyzoite antigen 1 
(BAG1), heat shock protein 70 (HSP70) and enolase 2 (ENO2) promoters are for the 
bradyzoites. For the regulatable promoter, the tetracycycline (tet) repressor system is 
the most effective system, also known as ‘tet off’ model (Meissner et al., 2001). In 
this system, the promoter is activated once the Tet operator (TetO) is occupied by the 
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Tet-transactivator protein (TetTA). When anhydrotetracycline (ATc) is present, TetTA 
is displaced from the TetO region. Consequently, the promoter is inactivated and in 
turn leads to the gene suppression (Fig. 1.1A; Meissner et al., 2007).  
 
 
 
 
 
Table 1.1 Applications of the reporter genes in T. gondii 
     (summarized from Gubbels et al., 2007) 
Reporter gene Examples Applications 
Enzyme CAT 
luciferase 
LacZ 
Enzymatic assay, colorimetric assay or 
bioluminescent assay for drug screening and 
growth comparison 
 
Bioluminescent imaging  
Epitope tagging HA 
Myc 
FLAG 
Subcellular localisation 
Protein processing 
Immunoprecipitation  
Fluorescence GFP 
YFP 
RFP 
Microscopic analysis  
Organelle biogenesis   
Parasite trafficking 
Growth assay 
Counter-selection by flow cytometry 
Reporters for  
animal models 
YFP-YFP 
luciferase 
Infection process  
Real-time imaging 
Toxoplasmosis and immunological studies 
Bioluminescent imaging and two-photon 
microscopy 
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1.1.2 The Establishment of Toxoplasma Mutants 
 
To evaluate the importance of a target gene, a detailed phenotypic analysis on its 
knock-out or knock-down depletion mutant can provide informative data regarding its 
specific functional roles. This section will briefly describe the approaches for the 
establishment of mutants in T. gondii.  
 
Gene knock-out approach in T. gondii is based on homologous recombination between 
the target locus in the genome and the modified locus presented in the transfected 
plasmid. Homologous recombination can be either single or double (Fig 1.1B; 
Striepen and Soldati, 2007). Although T. gondii is haploid organism, the generation of 
knock-out mutants is still not an easy task due to the high frequency of non-
homologous recombination. One improved strategy is to increase the homologous 
regions (Donald and Roos, 1994) in order to increase the frequency of homologous 
recombination. An alternative approach is to introduce a negative selection marker 
that can be used to counter-select against the non-homologous integration (Mazumder 
et al., 2006). The latest approach is to use a mutant parasite strain deficient in end-
joining repair mechanisms for the non-homologous recombination, which can 
efficiently achieve gene replacement (Fox et al., 2009; Huynh and Carruthers, 2009).  
 
In case of studying an essential gene in T. gondii, a ‘tet-off’ based conditional knock-
out approach is commonly used. First, a parental parasite line is stably transfected 
with an additional copy of the target gene, which can be suppressed by a tetracycline 
repressor system (Meissner et al., 2002; see Section 1.1.1). Secondly, the endogenous 
target gene is knocked out in these parasites. As a result, the exogenous copy of the 
target gene in knock-out mutant can be suppressed in the presence of ATc. Another 
approach is using site-specific recombination to temporally knock out the target gene 
by using inducible recombinase such as Cre or Flp, which was reported in 
Plasmodium (Carvalho et al., 2004). Although the site-specific system was 
successfully established in T. gondii (Brecht et al., 1999), a ‘tet-off’ based 
recombination system has not yet established (Meissner et al., 2007). 
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Figure 1.1 Genetic manipulation in T. gondii. (A) The ‘tet off’ system. It consists of a 
cascade of Tet-Operator (TetO) DNA repeats and Tet-transactivator protein (TetTA), 
a fusion of E. coli Tet-repressor and T. gondii transactivating domain. In the absence 
of anhydrotetracycline (ATc), the TetTA is bound to the TetO repeat that activates the 
promoter and in turn leads to the gene expression. In the presence of ATc, the 
promoter is inactivated due to the displacement of TetTA from the TetO repeats 
(modified from Meissner et al., 2007). (B) Schematic diagram describing gene knock-
out approach through double (left panel) or single homologous recombination (right 
panel). The transfected plasmid (linear plasmid on left panel; circular plasmid on right 
panel) contains a selection cassette CAT and the homologous regions (white boxes) or 
even a negative selection marker such as YFP. A crossover event leads to the 
disruption of the endogenous gene locus (adapted from Striepen and Soldati, 2007). 
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For gene knock-down, recent studies have adapted a ligand-regulatable FKBP 
destabilization domain (ddFKBP) to control the protein expression both in 
Plasmodium and Toxoplasma (Armstrong and Goldberg, 2007; Herm-Gotz et al., 
2007). This system is modified from the original finding (Banaszynski et al., 2006) 
that an engineered human FKBP12 was able to be stabilized by the binding of a 
synthetic ligand, called Shield-1 (Shld1). When ddFKBP is fused a target protein, the 
destabilization domain causes the degradation of the fusion protein. But in the 
presence of Shld-1, this domain is stabilized so that the fusion protein is able to be 
expressed. Accordingly, the parasites expressing ddFKBP-MyoA fusion were 
successfully and reversibly regulated in Shld1-dependent manner within few hours 
(Herm-Gotz et al., 2007). Such a rapid protein regulation will be an impressive tool in 
studying the protein functions in apicomplexan parasites.  
 
Another feasible method for gene knock-down is the application of RNA interference 
(RNAi). It has been predicted that the Toxoplasma but not Plasmodium genome 
encodes the necessary proteins for the RNAi pathway (Ullu et al., 2004). Previous 
works also have demonstrated that by using hammerhead ribozymes and dsRNA could 
significantly suppress the target mRNA (Al-Anouti and Ananvoranich, 2002; Al-
Anouti et al., 2003). However, the application of RNAi in T. gondii is still uncertain 
since several groups failed to knock down their target genes by using this approach 
(Gubbels et al., 2007). Since RNAi technique is around the corner and has been 
successfully applied to different organisms, it remains a considerable alternative for 
gene knock-down in T. gondii in the future.  
 
1.2 T. gondii as a Model System for Apicomplexan Drug Discovery 
 
In the past decades, the widespread of drug resistance has emerged as a major 
impediment to the treatment of parasitic diseases. In particular, malaria resistance to 
chloroquine has been increasingly reported throughout many endemic regions (Carlton 
et al., 2008; Fidock et al., 2008). Therefore, the development of a novel and potent 
antiparasitic drug is essential. Several emerging novel drug targets, including the 
apicoplast metabolic pathways, the mitochondrial enzymes, and the histones involved 
in epigenetic regulation, sound promising and attractive (Table 1.2; Donald, 2007; 
Fidock et al., 2008). However, it should be noted that the members in Apicomplexa 
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have their diversity of metabolism. These drug targets may not be applicable to all the 
members. Therefore, the validation of drug target is another important topic of drug 
discovery. Moreover, it should be emphasized that drug resistance can only partly 
explain the chemotherapeutic failure. Under this circumstance, drug validation will 
provide critical information for improving the drug efficacy. Although drug resistance 
currently seems not a major clinical issue for the treatment of T. gondii (McFadden et 
al., 2001), T. gondii has been implicated in the discovery of antiparastic drugs as well 
as used for the validation of drug targets (Donald, 2007). Some examples of using 
Toxoplasma as a model for drug identification and target validation will be delineated 
in the following section. 
 
1.2.1 The Identification of Drug Targets  
 
Previous studies have observed that the antibiotics such as tetracycline, macrolides 
and clindamycin could efficiently protect against several parasitic infections (Luft and 
Remington, 1988; Roos et al., 1999; McFadden et al., 2001). These antibiotics are 
known to inhibit bacterial translation, suggesting that the protozoan parasites may 
possess similar prokaryotic translation machinery. Specifically, one typical example is 
the large subunit antibiotics including macrolides and lincosamides, which targets the 
large subunit of the ribosome in prokaryotes. When Toxoplasma and Plasmodium both 
were treated with these antibiotics, a delayed replication was consistently observed 
(Divo et al., 1985; Fichera et al., 1995). Initially, it was thought that the antibiotics 
targeted at mitochondrial translation. Until the identification of the non-photosynthetic 
plastid-like sequence from Plasmodium in late 1990s, it partly explains the inhibitory 
effects of these prokaryotic antibiotics. However, the clear evidence provided actually 
was obtained in Toxoplasma indicating that the apicoplast is indeed the target of these 
antibiotics. First, DNA hybridization analysis provides direct evidence that the plastid 
genome was selectively lost in response to clindamycin treatment (Fichera and Roos, 
1997). Secondly, experiment results showed that the cytosolic and mitochondrial 
protein syntheses were not affected by these antibiotics (Beckers et al., 1995). 
Moreover, the plastid DNA gyrases were identified as the targets for ciprofloxacin, a 
fluoroquinolone compound (Fichera et al., 1995). Taken together, T. gondii has been 
used as an important model to identify that the apicoplast is the target organelle 
(Beckers et al., 1995; Fichera and Roos, 1997).  
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Table 1.2 Novel drug targets in Plasmodium and Toxoplasma  
(summarized from Donald, 2007; Fidock et al., 2008) 
 
Targets  Specific pathways involved 
Apicoplastic metabolism 1-deoxy-D-xylulose 5-phosphate reductase 
 
Lipid metabolism 
 
Protein synthesis and transcription 
Cytoskeletal proteins Tubulin polymerization  
Cytosolic pathways Choline synthesis 
 Shikimate pathway 
 Thioredoxin reductase 
 Vitamine B6 synthesis 
Epigenetic regulation Histone deacetylase and acetyltransferase 
Mitochondrial enzymes Dihydroorotate dehydrogenase  
 Electron transport enzyme complexes 
Proteases Subtilisin-like proteases 
 Cysteine/aspartic proteases 
Protein kinases Cyclin-dependent kinases 
(Doerig et al., 2008) Caesein kinase 1 
Transporters V-type H+- ATPase 
 Folate-biopterin transporters 
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Since T. gondii is amenable to genetic manipulation, using complementation strategy 
is another method for target validation. An earlier work has shown that a 
Cryptosporidium library could complement T. gondii HXGPRT-deficient mutant in 
the presence of mycophenolic acid, an inosine 5-monophosphate-dehydrogenase 
(IMPDH) inhibitor that prevents purine salvage pathway. This finding identified that 
the IMPDH (Striepen et al., 2002) is as a promising target against Cryptosporidium 
parvum. Due to the difficulty of in vitro propagation of Cryptosporidium, T. gondii is 
a useful tool for studying the nucleotide metabolism of C. parvum (Striepen et al., 
2004). Moreover, Toxoplasma has been used as a model for understanding 
apicomplexan lipid metabolism and cytoskeletal architecture. Chemotherapeutic 
targets of the fatty acid synthesis (FAS) II pathway and tubulin polymerization have 
been validated in T. gondii (Donald, 2007).  
 
1.2.2. The Validation of Drug Targets 
 
The mitochondrial complex III inhibitor atovaquone is one of the effective antimalaria 
drugs. However, the target of atovaquone was identified with the help of Toxoplasma. 
Atovaquone belongs to the hydroxynapthoquinone compound, which is structurally 
similar to ubiquinone (CoQ), the electron carrier in the respiratory chain. CoQ can 
occupy cytochrome bcB1 Bcomoplex at QB1B site to accept electrons and at QBoB site to 
donate electrons. Although biochemical analysis in Plasmodium suggests that 
atovaquone interferes with ubiquinone by targeting at the cytochrome bcB1B complex 
(Fry and Pudney, 1992), the identification of the atovaquone binding site was 
eventually validated in Toxoplasma (McFadden et al., 2000). Two mutation sites were 
identified in the QBoB domain of the cytochrome b gene from the atovaquone-resistant 
mutant (Pfefferkorn et al., 1993), suggesting that either of these two mutations within 
the QBoB domain is the key for the drug resistance. Additionally, parasites resistant to 
another mitochondrial inhibitor decoquinate were observed with a similar mutation 
within the QBoB domain (McFadden and Boothroyd, 1999), indicating that atovaquone 
and decoquinate both inhibit the activity of QBo Bdomain. Later on, the atovaquone-
resistant Plasmodium was analysed revealing that the mutated residues consistently 
were restricted to the QBo Bdomain. In vitro drug resistant parasites have become an 
important tool to identify and validate drug targets. 
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Besides, T. gondii was used as a model to validate the drug target of compound 1 in 
Eimeria (Donald et al., 2002; Donald and Lieberator, 2002) regarding its biological 
similarity. However, the life cycle of Eimeria cannot be completed in vitro, direct drug 
validation in Eimeria is very limited. T. gondii was firstly used for heterologous 
expression of the Eimeria cGMP-dependent protein kinase (PKG) that was failed to be 
expressed in other systems including E. coli and yeast (Gurnett et al., 2002). When 
Eimeria PKG was transfected into PKG-resistance mutants, parasites were resistant to 
compound 1, suggesting that PKG is the major target for compound 1. More drug 
validation on the other PKG inhibitors and the identification of the second targets of 
PKG inhibitors were performed in Toxoplasma (Donald, 2007).  
 
1.3 Apicomplexan Organelles 
 
The phylum Apicomplexa is characterized by an apical complex of cytoskeletal 
structures and secretory organelles (Nishi et al., 2008). These organelles including the 
micronemes, the rhoptries and the dense granules all are engaged in invasion process 
(Carruthers and Sibley, 1997; Black and Boothroyd, 2000). Most of the apicomplexan 
parasites also contain the eukaryotic organelles such as endoplasmic reticulum, 
mitochondrion and nucleus. Additionally, a plastid-like organelle, called apicoplast, is 
identified in most of the apicomplexa parasites including Toxoplasma and 
Plasmodium. The subcellular organelles in Toxoplasma are illustrated in Fig 1.2 and 
Table 1.3. 
 
1.3.1 Apicoplast and Mitochondrion as promising Drug Targets 
 
Among these organelles in apicomplexan parasites, apicoplast and mitochondrion are 
considered as the intriguing targets for drug development. The apicoplast, a non-
photosynthetic plastid-like organelle, is believed to be the product of a secondary 
endosymbiotic event. Genomic analysis indicates that the apicoplast in Toxoplasma 
and Plasmodium is responsible for many essential pathways such as fatty acids, 
isoprenoid and heme syntheses (Roos et al., 1999; Ralph et al., 2004). Because of its 
uniqueness in apicomplexan parasites, it has been regarded as a promising organelle 
for drug development. More importantly, previous works have clearly demonstrated 
that the apicoplast was essential for parasitic replication and survival (Fichera and 
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Roos, 1997; Mazumdar et al., 2006). Moreover, the metabolism taking place in the 
apicoplast is more related to the prokaryotic pathways (Kim and Weiss, 2004), 
implying that the drugs target very specifically to the parasites rather than the 
mammalian cells. Collectively, these intriguing observations have ushered the 
apicomplexan apicoplast as a potential candidate for the strategic drug discovery. 
 
The apicomplexan mitochondrion is considered another important antiparasitic target 
owing to the significant difference of the energy metabolism adapted in parasites as 
compared to their host cells. One of the key mitochondrial targets is the respiratory 
chain, also known as the electron transport chain (ETC). It includes the complex III 
inhibitor atovaquone, which has been widely used against Plasmodium (Looareesuwan 
et al., 1999) and Toxoplasma (McFadden et al., 2001). The specificity of this 
compound acting on the mitochondria has been experimentally validated (Srivastava 
et al., 1997; Krungkrai, 2004). Further experimental results have revealed the 
promising antiparasitic effects from the other mitochondrial respiratory inhibitors 
(Omura et al., 2001; Biagini et al., 2006), suggesting that the enzyme complexes in 
the respiratory chain are the promising targets. More recent, the mitochondrial enzyme 
dihydroorotate dehydrogenase (DHOD) has been identified as a potential target 
against Plasmodium (Painter et al., 2007). DHOD is the fourth enzyme of the essential 
pyrimidine de novo biosynthetic pathway that requires ubiquinone as electron acceptor. 
It demonstrated that the over-expression of ubiquinol-independent DHOD could resist 
to the atovaquone, suggesting that the role of complex III in Plasmodium is to recycle 
ubiquinone for DHOD. This finding once provoked a heat debate since it suggested 
that other mitochondrial dehydrogenases are non-essential in Plasmodium (Vaidya et 
al., 2007; Fisher et al., 2007). Because of the urgency of drug-resistance in malaria, it 
may be too early to exclude other potential targets. To combat the parasitic diseases, 
the current challenge is to improve the drug efficacy and the drug specificity by using 
combinatory treatments.  
 
1.3.2 The Apicomplexan Mitochondrial Respiratory Chain 
 
The importance of the mitochondrial respiratory chain in the apicomplexan parasites is 
evident with the antiparasitic effects by several ETC inhibitors (Srivastava et al., 1997; 
Vercesi et al., 1998; Biagini et al., 2006). Previous studies demonstrated that using 
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this kind of inhibitors led to a dramatic collapse of ∆ψBmB in Plasmodium and even 
caused parasite deaths (Srivastava et al., 1997; Biagini et al., 2006). These 
observations clearly indicate that the mitochondrial respiratory chain is essential to 
maintain the mitochondrial functions. However, the importance of the respiratory 
chain in Plasmodium remains controversial since the biochemical data indicates that 
the ATP source in the erythrocytic stage is mainly obtained from glycolysis rather 
than from the respiratory chain (van Dooren et al., 2006). 
 
On the other hand, the respiratory chain in Toxoplasma seems to play a pivotal role in 
energy metabolism. Toxoplasma harbours the complete sets of enzymes for the 
glycolytic pathway and the tricarboxylic acid (TCA) cycle (Fleige et al., 2007, 2008). 
Therefore, the respiratory chain is expected to maintain the NADH/NADP+P ratio since 
the recycled NADP+P is necessary to make other metabolic pathways to be functioned. 
Secondly, the complexes of the respiratory chain are responsible for the establishment 
of the electrochemical photon gradient that can provide the driving force for ATP 
synthase (ATPase; Vercesi et al., 1998).  
 
So far, no direct evidence has been provided about the mitochondrial activities in 
Babesia and Theileria (Seeber et al., 2008). Moreover, Cryptosporidium, the much 
more evolutionary distant parasite as compared to Toxoplasma, does not encode the 
components for the respiratory chain due to the absence of the typical mitochondrion. 
Instead, this parasite possesses an organelle, called mitosome, which contains an 
alternative terminal oxidase for direct electron transfer from ubiquinone to OB2B   
 
Nevertheless, the majority of the apicomplexan parasites possess the components for 
the respiratory transport chain. The following section will depict these common 
features of the respiratory chain. 
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Figure 1.2 Organelles and subcellular structures of T. gondii. (A) Schematic 
representation of the organellar arrangement in tachyzoite stage (adapted from Nishi et 
al., 2008). (B) Cytoskeletal network of T. gondii. MT, microtubules. (adapted from Hu 
et al., 2006) 
 
 
Table 1.3 Functions of the unique organelles in T. gondii 
(summarized from Dubey et al., 1998; Black and Boothroyd, 2000) 
 
Organelle Functions 
Apicoplast (Roos et al., 1999) Fatty acid synthesis   
 Heme biosynthesis 
 Isoprenoid biosynthesis 
Cytoskeleton (He et al., 2006) Including conoid, the polar rings, the microtubules 
(MT), and the inner membrane complex  
 To provide the structural integrity 
 To direct the protein secretion during invasion 
 For gliding on host cell surfaces  
Dense granules Involved in the late invasion process 
Micronemes Host attachment in the early invasion process 
Micropore Acting as the active site of endocytosis 
Rhoptries An important role in parasite virulence 
 Containing proteolytic enzymes for host cell 
penetration during invasion process 
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1.3.2.1 Oxidation Phosphorylation  
 
The mitochondrial respiratory chain, also known as the electron transport chain, plays 
a very significant role in the production of ATP through the process called oxidation  
phosphoryation. This process involves two steps – the release of the free energy 
during the electron transport, and the generation of the electrochemical photon 
gradient that provides the free energy for ATPase. The whole process involves the 
consumption of oxygen and the catalysis of ADP to ATP. It is thus called oxidative 
phosphorylation (Scheffler, 2001).  
 
The mechanism of oxidation phosphorylation is described as follows. Firstly, the 
electron transport starts as the high-energy electrons are converted from a hydride ion 
(H:-) being removed from NADH or FADHB2. BThe electrons next are passed along the 
enzyme complexes through a series of oxidation-reduction reaction, where the 
ubiquinone and cytochrome c act as mobile carriers to transfer the electrons between 
the complexes. The electron transport is energetically favorable so that the electrons 
are readily to be passed along the chain. Eventually the released energy allows the 
enzymes complexes III and IV (also complex I in mammalian cells) to pump the HP+P 
from the matrix into the intermembrane space. This pumping action eventually 
generates an electrochemical proton gradient across the inner mitochondrial 
membrane, which is composed of a gradient of proton concentration and a membrane 
potential. The latter component contributes the majority of the electrochemical proton 
gradient. Consequently, this gradient drives the flow of HP+P back to the matrix through 
ATPase. The ATPase uses the released energy to synthesize ATP from ADP in the 
matrix.   
 
Further information about the reducing equivalents NADH and FADHB2B mentioned 
above should be described here. They can be generated from the TCA cycle in 
mitochondrial matrix or transferred from cytosol into mitochondrion by metabolic 
glycerol-3-phosphate (G3P) shuttle or/and malate/aspartate shuttle. However, it is still 
unclear whether these metabolic shuttles exist among the apicomplexan parasites. In 
Toxoplasma, G3P shuttle is very likely to be present, which is based on the 
identification of the cytosolic localized glycerol-3-phosphate dehydrogenase (G3PDH; 
Fleige et al., 2007). Also, this shuttle is suggested to be present in Plasmodium (Fry 
          Page 15                       
Chapter I Introduction 
and Beesley, 1991; Uyemura et al., 2004). Experiments have demonstrated that the 
addition of exogenous G3P could stimulate the respiratory chain (Uymera et al., 2004). 
Additionally, both NADP+P-linked and FAD-linked G3PDH are predicted in the 
Plasmodium genome (van Dooren et al., 2006). However, no supportive evidence 
exists so far for the presence of the malate/aspartate shuttle among the apicomplexan 
parasites. In spite of this, the reducing equivalents NADH or FADHB2B donate their 
high-energy electrons into the respiratory chain, which is catalyzed by several 
dehydrogenases. The details of the other dehydrogenases in T. gondii are summarized 
in Table 1.4.  
 
Like the mammalian cells, the apicomplexan parasites contain the similar components 
in the respiratory chain, including the enzyme complexes, ubiquinone and cytochrome 
c (Fig. 1.4; van Dooren et al., 2006; Seeber et al., 2008). The apicomplexan enzyme 
complexes are type II NADH dehydrogenase (NDH2; single subunit), complex II 
(succinate: ubiquinone oxidoreductase), complex III (cytochrome bcB1B complex), 
complex IV (cytochrome oxidase), and complex V (ATPase). Among these enzyme 
complexes, the apicomplexan parasites possess NDH2 (single subunit) instead of 
conventional complex I present in mammalian cells. Nevertheless, they share similar 
function as that in the mammalian cells. Further information of the respiratory enzyme 
complexes is illustrated in Fig 1.3 and Table 1.5. 
 
1.3.3 Type II NADH Dehydrogenases  
 
NDH2, also known as the alternative complex I, has been described in prokaryotes, 
plants, fungi and many apicomplexan parasites, with the exception in mammals 
(Kerscher, 2000; Weinstein et al., 2005; Biagini et al., 2006; Saleh et al., 2007). 
Compared to the conventional NADH dehydrogenase (complex I) and the prokaryotic 
sodium pumping NADH dehydrogenases, NDH2 does not possess any proton or 
sodium pumping property due to the absence of energy-transducing sites. Our current 
knowledge of this atypical NDH2 is still very limited. However, it is generally 
accepted that the main function of NDH2 is to catalyze the transfer of the electrons 
from NAD(P)H to quinone in the respiratory chain, which in turn contributes to the 
production of ATP. Up to now, it remains a mystery why these organisms favor 
NDH2 instead of complex I as expressed in mammalian cells, or co-express NDH2 
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together with the complex I. The commonly accepted hypothesis for this phenomenon 
is to minimize the formation of the reactive oxygen species since complex I is one of 
the major sources of the superoxide anion radicals in mitochondria (Fisher et al., 2007; 
Kerscher et al., 2008). Apart from that, an additional advantage for the presence of 
NDH2 proposed in Plasmodium is to balance of the proton gradient in the respiratory 
chain (Fisher et al., 2007). As suggested, parasites adapted in a microaerophilic 
environment may not produce extensive ATP by oxidative phosphorylation. Therefore, 
they have to adjust the proton gradient either by reducing the protons to be pumped 
into the intermembrane space or by modifying the membrane components such as the 
expression of uncoupling proteins (Uyemura et al., 2004) that allows the re-entry of 
protons to the matrix. Because of the non-proton pumping property of NDH2, this 
may be a possible purpose for this enzyme to reduce the proton ‘back-pressure’ in 
Plasmodium respiratory chain (Fisher et al., 2007).  
 
1.3.3.1 Structural Characteristics of NDH2s 
 
NDH2s are single polypeptides usually with the molecular masses of 50-60 kDa. They 
possess two characteristic regions called GXGXXG motifs that consist of the βαβ 
domain for the binding of NAD(P)H and the cofactor flavin adenine dinucleotide 
(FAD) or flavin mononucleotide (FMN). The first GXGXXG motif is located near to 
the N-terminus and has been predicted as the non-covalent binding site for FAD. This 
prediction is based on the X-ray crystallography data of the bacterial lipoamide 
dehydrogenase, showing that FAD binds to the first βαβ domain. A previous study has 
suggested that NDH2 and lipoamide dehydrogenase in bacteria share a common 
ancestry (Bjorklof et al., 2000). Beyond these two motifs, some NDH2s, such as 
Solanum tuberosum and Neurospora crassa, contain an additional CaP2+P EF-hand motif, 
which is responsible for membrane interaction (Melo et al., 2004). According to the 
arrangements of the binding motifs, NDH2s can be clarified into three groups A, B 
and C (Fig. 1.4A; Melo et al., 2004). Group A containing both βαβ domains can be 
found in eukaryotes, bacteria and archeae. Group B is similar to group A with an 
additional EF-hand motif, mainly found in eukaryotes such as plants and fungi. Group 
C only conserves a single βαβ domain, which is restricted to hyperthermophilic 
archeae. 
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Table 1.4 Properties of the dehydrogenases in T. gondii 
Dehydrogenase Localization (expected) Properties 
Dihydroorotate 
dehydrogenase 
(DHOD) 
 
Mitochondrion 
 
NADP+P-linked 
glycerol-3-phosphate 
dehydrogenase I 
(G3PDH I) 
(Fleige et al., 2007) 
 
FAD-linked G3PDH 
(putative) 
Cytosol 
 
 
 
Mitochondrion 
 
 
 
 
 
Isocitrate 
dehydrogenase I 
(Fleige et al., 2008) 
 
Mitochondrion  
(TCA cycle in matrix) 
 
α-ketoglutarate 
deydrogenase  
complex 
 
Mitochondrion 
(TCA cycle in matrix) 
 
Branched-chain α-keto 
acid dehydrogenase 
complex 
(Fleige, 2006) 
Mitochondrion 
 
Malate dehydrogenase 
(Fleige et al., 2008) 
Mitochondrion  
(TCA cycle in matrix) 
 
FAD-dependent 
malate:ubiquinone 
oxidoreductase 
(Fleige et al., 2008) 
Mitochondrion 
 
Oxidizing electrons from 
FADHB2B to CoQ 
Succinate:ubiquinone 
oxidoreductase 
(Saleh, 2006) 
Mitochondrion 
(inner membrane) 
 
Oxidizing electrons from 
FADHB2B into CoQ 
Type II NADH 
dehydrogenases 
(TgNDH2-I & -II) 
(Lin et al., 2008) 
Inner mitochondrial 
membrane  
(orientation is investigated  
in this study) 
Oxidizing electrons from 
NADH to CoQ 
 
 
    G3P DHAP 
FADP FADHB2 
oxaloacetate 
NADP+ NADH 
FADP FADHB2 
NADP+ NADHB2PB 
succinyl-CoA α-ketoglutarate  
R-CHNH3P+P-COOP-P R-CO-S-CoA 
NADHB2 NADP+P 
isocitrate  α-ketoglurtarate 
orotate 
CoQHB2 
dihydroorotate  
CoQB 
NADP+ NADHB2 
end products are branched-chain 
acyl CoAs 
succinate  fumarate 
malate  
  DHAP 
NADHP NADP+PB 
G3P 
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Figure 1.3 Model of the apicomplexan mitochondrial respiratory chain. (A) The major 
components are enzyme complexes, ubiquinone (CoQ) and cytochrome c. The enzyme 
complexes are type II NADH dehydrogenase (single subunit; NDH2), complex II 
(succinate: ubiquinone oxidoreductase), complex III (cytochrome bcB1B complex), 
complex IV (cytochrome oxidase), and complex V (ATPase) (B) The sequential 
electron carriers in the respiratory chain. The enzyme complexes may contain 
prosthetic group (FMN or FAD) that facilitates the catalytic reaction, and iron-sulfur 
(Fe-S) proteins, where a serial of oxidoreduction reaction is taking place. Cyt c, 
cytochorome c; CoQHB2B, ubiquinol (reduced CoQ). 
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Table 1.5 Structural and functional properties of the apicomplexan respiratory complexes  
(summarized from Saraste, 1999) 
Component Structural properties Functions 
Type II NADH 
dehydrogenase 
One single subunit   
Containing FAD or FMN 
Transfer electrons from NADH to CoQ 
A role in maintaining ∆ψBmB in Plasmodium 
(Biagini et al., 2006) 
Complex II 
(Succinate: 
ubiquinone 
oxidoreductase) 
~ 4 subunits  
Containing one FAD or FMN and several 
iron-sulfur center 
A component in the TCA cycle 
Transfer electrons from FADHB2 Bto CoQ  
Complex III 
 
(Cytochrome bcB1B 
complex) 
~ 9-10 subunits 
Containing diheme cytochrome c, 
cytochrome c1 and Rieske iron-sulfur 
center 
One subunit is encoded by mitochondrial 
DNA (mtDNA; in mammalian cells ) 
Transfer electrons from ubiquinol (CoQHB2B)                                 
to cytochrome c  
Proton-pumping property 
Two active sites including Q for the oxidation of 
CoQHB2B and release of protons, andB BQB1B for reduction 
of CoQ 
Complex IV 
(Cytochrome 
oxidase) 
13 subunits   
3 major subunits are encoded by mtDNA 
Subunits contain Fe/Cu centres 
Reduce oxygen to water 
D channel is essential for proton pumping activity 
Complex V 
(ATPase) 
FB0 B(a,b,c) and FB1B (α,β,γ,δ,ε) subunits  
(is diverged among the parasites; Seeber 
et al., 2008) 
Two subunits are encoded by mtDNA 
(in mammalian cells ) 
Both ATP synthesis and hydrolysis 
Proton-pumping property 
FB0B contains proton channel and FB1B contains catalytic 
component 
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Although the primary structure of the NDH2s seems very highly conserved, several 
features such as the substrate specificity and the cofactor preference are far from our 
understanding. First, some NDH2s have been reported to be able to oxidize both 
NADH and NADPH (Rasmusson et al., 2004; Geisler et al., 2007) substrates. This 
kind of substrate specificity seems very difficult to extract from the primary structures. 
Although several prediction models have been proposed for the specificity for 
NAD(P)H, it is not widely applied (Bernard et al., 1995; Melo et al., 2004). 
Accordingly, the second β sheet in the putative NADH binding domain (second 
GXGXXG motif) is usually ended with an acidic residue, glutamate or asparate. One 
explanation is that these negative charged amino acids will repel the negative charges 
of the phosphate group of NADPH, rendering NADH as the specific substrate. In N. 
crassa, the NADH dehydrogenases have conserved acidic residue GluAla (EA) or 
AspVal (DV), whereas the NADPH dehydrogenases encode GlnSer (QS) instead (Fig. 
1.5B; Michalecka et al., 2004). Additional experiments have demonstrated that a 
single mutation of aspartate to neutral amino acid in NADH lactate dehydrogenase and 
formate dehydrogenase can modify the enzyme specificity to accept NADPH in 
addition to their original substrates (Feeney et al., 1990; Gul-Karaguler et al., 2001). 
These are striking findings in plant biology since using NADPH as substrate may be 
advantageous to overcome the oxidative stress (Michalecka et al., 2004). However, 
using primary structure to evaluate the substrate specificity is still used a reference, the 
ultimate step requires experimental validation. Regarding the identification of the 
cofactors associated within NDH2s, it is unlikely to be speculated from the primary 
structure. The associated cofactors are more likely to be species-dependent and only 
experimental results can reveal their interaction with the binding domains in NDH2s.  
 
1.3.3.2 Membrane Interaction of NDH2s  
 
Each single mitochondrion in eukaryotic cells contains two membrane-bounded 
compartments, the internal space, called matrix, and the intermembrane space. These 
two compartments are created by the outer and the inner mitochondrial membranes, 
both are comprised of a lipid bilayer. In particular, the inner mitochondrial membrane 
contains most of the proteins that are responsible for the respiratory chain and for 
metabolite exchanges.  
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NDH2 is known to be localized to the inner mitochondrial membrane as a component 
in the respiratory chain. However, the mechanism involved in the membrane 
anchoring in this enzyme remains unclear. Bioinformatics analyses of the primary 
structures of the NDH2s from different species are unable to predict any 
transmembrane helices (Melo et al., 2004). A widely accepted model is that NDH2 
attaches to the membrane using amphipathic α-helices (Bandeiras et al., 2002; Melo et 
al., 2004), where the hydrophobic and hydrophilic residues are situated on the 
opposite sides on the helical surface. This kind of helices is predicted to be present in 
the secondary structures in the majority of the NDH2s (Melo et al., 2004). For 
instance, Plasmodium NDH2 is predicted with a C-terminal amphipathic α-helices 
(Fisher et al., 2007). Additionally, the interaction of NDH2 with the membrane seems 
very strong based on the observation that the activity of NDH2 could be increased 
with a longer incubation with the lipids (Bjorklof et al., 2000; Gomes et al., 2001). As 
predicted in Plasmodium NDH2, some residues within the amphipathic helices can be 
oriented in the bilayer that the headgroups are directly interacted with the membrane. 
Under this circumstance, the direct electrostatic interaction between NDH2 and the 
bilayer can be a reasonable explanation for the importance of lipid environment for the 
enzyme activity. 
 
One major function of NDH2 is to transfer electrons from NADH into quinone 
(including ubiquinone) in the respiratory chain. Due to the interesting combination of 
electron transfer between the hydrophilic NADH and the hydrophobic quinone, it is 
generally accepted that the quinone (Q) sites are interfaced at the membrane surface. 
To be more specific, the hydrophilic headgroup of the quinone is more likely to 
interact with the enzyme since the reduction to quinol requires the proton that is in the 
aqueous phase. This speculation implies that the ubiquinone-binding site in NDH2 is 
more specific to the ubquinone headgroup (Eschemann et al., 2005). Although Fisher 
and Rich have proposed two types of quinone-binding sites (Fischer and Rich, 2000) 
in NDH2, which is characterized by a putative conserved histidine or tyrosine residues, 
it is not widely applicable due to the diversity of NDH2s. The quionone-binding 
regions still are unpredictable from the primary structures and most of the available 
quionone-binding sites are based on the predictions from comparative modeling 
          Page 22                       
Chapter I Introduction 
(Fischer and Rich, 2000). X-ray crystallography data are crucial to unveil the exact 
quinone-binding sites for NDH2s.  
 
 
Figure 1.4 Eukaryotic type II NADH dehydrogenases. (A) Classification of NDH2s is 
based on the arrangement of the binding motifs. They are listed as follows: two βαβ 
binding motifs for group A; two βαβ binding motifs and one EF-hand motif for group 
B; and one βαβ binding motif for group C (modified from Melo et al., 2004). (B) 
Comparison of the substrate specificity for NAD(P)H from the putative NAD(P)H-
binding domain in eukaryotic NAD(P)H dehydrogenases. The last two residues at the 
second β sheet showing that NADH dehydrogenases may have conserved acidic 
residue GluAla (EA) or AspVal (DV) but NADPH dehydrogenases have a preference 
for GlnSer (QS) (modified from Michalecka et al., 2004). 
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1.3.4 Electrophysiology of Mitochondrial Membrane Potential  
 
 
As mentioned above, the mitochondrial membrane potential (∆ψBmB) is the major 
component of the electrochemical proton gradient that is built up as a consequence of 
proton pumping by the respiratory chain. In mammalian cells, the proton gradient 
yields a total energy about 240 mV, containing of 180 mV mainly from ∆ψBm Band 60 
mV from the pH gradient. Although this kind of data has not yet been available in 
apicomplexan parasites, the physiological impacts of the ∆ψBm Bare expected to be 
similar to that in mammals. One of the physiological functions of the ∆ψBm Bis to 
provide the energy stored in proton gradient for the ATPase to synthesize ATP, the 
energy source. Interestingly, the magnitude of the proton gradient can be varied from 
different cell types and differentiation stages in mammals. For instance, some cancer 
cells and myoblasts can adjust their membrane potentials in accordance to their needs 
in the differential stages (Chen et al., 1988).  
 
Indeed, the regulation of the proton gradient plays an important role in cellular 
functions. It affects the transport of metabolites, the import of the precursor proteins 
and mitochondrial protein synthesis. In particular, the importance of ∆ψBmB in 
mitochondrial trafficking will be addressed here. Protein import into mitochondrion 
can be achieved by several pathways such as the common N-terminal presequence, 
tail-anchor sequence and internal signal. Mitochondrial import machinery consists of 
the translocase of the outer membrane (TOM) complexes and the translocase of the 
inner membrane (TIM) complexes, which processes the proteins targeting beyond the 
outer membrane. Specifically, the transport of the precursor mitochondrial proteins via 
the TIM23 and TIM22 requires membrane potential and ATP (Truscott et al., 2003). 
First, the membrane potential supports the transport of the positively charge 
presequences through the complexes pore into negatively charge matrix, Secondly, the 
ATP-dependent mitochondrial HSP70 drives the protein translocation into the matrix. 
These observations clearly implicates the role of ∆ψBm Bin proteinB Btrafficking and 
mitochondrial function.  
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1.4 Objectives of the Study 
 
The uniqueness of type II NADH dehydrogenases (NDH2s) in the apicomplexan 
respiratory chain defines these enzymes as a promising drug target. However, the 
specific roles and the importance of NDH2s (TgNDH2-I and -II) in Toxoplasma are 
still unknown.  
 
The previous study from my current group has shown that the quinolone-like 
compound 1-hydroxy-2-dodecyl-4(1)quinolone (HDQ) could effectively inhibit the 
replication of T. gondii with an impressive low ICB50B in the nanomolar ranges (Saleh et 
al., 2007). Although HDQ is first identified as a high affinity inhibitor for Yarrowia 
NDH2 (Eschemann et al., 2005), no experimental data so far has been investigated in 
the apicomplexan orthologs. To follow up this observation, it is particularly important 
to perform biochemical assays to provide the direct evidence showing that TgNDH2s 
are indeed the drug targets of HDQ. In this study, the detailed enzymatic parameters 
including the steady-state kinetics and inhibition kinetics will be investigated.  
 
Secondly, the physiological impact of TgNDH2s in the respiratory chain will be 
explored including the mitochondrial membrane potential and the parasitic ATP level. 
These findings will unveil the important role of TgNDH2s in the process of oxidative 
phosphorylation and their influences in mitochondrial functions. Additionally, the 
mitochondrial physiology between the tachyzoites and bradyzoites will be compared 
to reveal their differences in energy dependency. Moreover, this study will elucidate 
the orientations of both TgNDH2 isoforms in order to understand their specific 
integration in energy metabolism. Furthermore, this study will be in an attempt to 
generate conditional TgNDH2s knock-out mutants. Phenotypic differences from the 
depletion mutants will answer the questions about the essence and the specific roles of 
TgNDH2s in T. gondii. 
 
Taken together, I expect this study will reveal the important role of TgNDH2s in the 
respiratory chain and provide the direct evidence that TgNDH2s are promising drug 
targets.
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CHAPTER II 
Materials and Methods 
 
2.1 Materials 
2.1.1 Cell Cultures 
2.1.1.1 T. gondii Strains  
 
RH Wild-type  
RH-TATi RH expressing a tetracycline-inducible transactivator 
system (Meissner et al., 2001)  
 
TgATP-β RH-TATi expressing T. gondii ATPase beta subunit 
with a C-terminal myc-tagged fusion (Saleh, 2006; Lin 
et al., 2009) 
 
TgCox19-GFP1-10 
 
RH-TATi expressing a putative T. gondii cytochrome c 
oxidase Cox19 (TGME49_054260) fused with a C-
terminal GFP1-10  
 
TgCytoC420-GFP1-10 RH-TATi expressing a putative T. gondii cytochrome c 
(TGME49_029420) fused with a C-terminal GFP1-10  
 
TgCytoC750-GFP1-10 RH-TATi expressing a putative T. gondii cytochrome c 
(TGME49_019750) fused with a C-terminal GFP1-10 
 
TgCytoC750-GS-GFP1-10 RH-TATi expressing TgCyto750 fused with a linker 
(GS)B4B to C-terminal GFP1-10  
 
TgCytoC750-LS-GFP1-10 RH-TATi expressing TgCyto750 fused with a linker 
LS(GGGGS)B2BAA  to C-terminal GFP1-10  
 
TgNDH2-I RH-TATi expressing T. gondii type II NADH 
dehydrogenase isoform I with a C-terminal myc-tagged 
fusion (Saleh, 2006; Lin et al., 2008) 
 
TgNDH2-II RH-TATi expressing T. gondii type II NADH 
dehydrogenase isoform II with a C-terminal myc-
tagged fusion (Saleh, 2006; Lin et al., 2008) 
 
∆TgNDH2-I Conditional TgNDH2-I knock-out mutant  
∆TgNDH2-II Conditional TgNDH2-II knock-out mutant 
TgNDH2-I-GFP11 RH-TATi expressing TgNDH2-I fused with a C-
terminal GFP11 
 
TgNDH2-I-GS-GFP11 RH-TATi expressing TgNDH2-I fused with an 
additional linker (GS)B4B  to C-terminal GFP11  
 
TgNDH2-I-LS-GFP11 RH-TATi expressing TgNDH2-I fused with an 
additional linker LS(GGGGS)B2BAA to C-terminal  
GFP11  
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TgNDH2-IB399B-GFP11 RH-TATi expressing truncated TgNDH2-I whose 
residues 1 to 399 are fused with GFP11 at C-terminus 
 
TgNDH2-IB487B-GFP11 RH-TATi expressing truncated TgNDH2-I whose 
residues 1 to 487 are fused with GFP11 at C-terminus 
 
TgNDH2-II-GFP11 RH-TATi expressing TgNDH2-II fused with a C-
terminal GFP11  
 
TgS9-RFP                         RH-TATi expressing a T. gondii mitochondrial 
targeting ribosomal protein S9 fused with a C-terminal 
RFP (Lin et al., 2009) 
 
TgSCSβ-GFP1-10 RH-TATi expressing T. gondii succinyl-CoA 
synthetase beta subunit (Fleige et al., 2008) fused with 
a C-terminal GFP1-10  
 
 
2.1.1.2 Mammalian Cell Lines 
 
HFF Human foreskin fibroblasts (HFF) 
143B Human osteosarcoma cell line (Jacobson et al., 1993; 
kindly provided by Dr. MP King) 
 
143B/206 Mutant 143B cells lacking mitochondrial DNA 
(Jacobson et al., 1993; kindly provided by Dr. MP 
King) 
 
 
2.1.1.3 Escherichia coli Strains 
 
BL21 CodonPlus-RIL 
 
Chemically competent cells (Strategene) 
DH5α Chemically competent cells (Invitrogen) 
TOP10 Chemically competent cells (Invitrogen) 
SW103 Electrocompetent recombineering cells (Warming et al., 
2005; provided by NCI-Frederick); Genotype: DY380 
(cro-bioA)<>araC-PB ADB Flpe gal+ 
 
 
2.1.1.4 Yarrowia lipolytica Strains 
 
GB 5.2 NDH2 deletion strain (Eschemann et al., 2005; kindly 
provided by Dr. S Kerscher); Genotype: Mat b; his-1; 
leu2-270; ura2; xpr2-322 
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2.1.2 Plasmids 
 
pBTG11  
 
For split GFP complementation – containing a 
phleomycin resistance maker used to generate a C-
terminal GFP11 fusion (van Dooren et al., 2008; kindly 
provided by Dr. B Striepen) 
 
pCTG1-10 
 
For split GFP complementation – containing a 
chloramphenicol resistance marker used to generate a 
C-terminal GFP1-10 fusion (van Dooren et al., 2008; 
kindly provided by Dr. B Striepen) 
 
pDrive  PCR cloning vector (QIAGEN PCR cloning kit) 
pET-16b-TgNDH2-I24 For recombinant expression in E. coli - encoding 
TgNDH2-I mature peptide fused with 10× His-tagged 
at N-terminus 
 
piBG For cosmid recombineering – used as a template for 
PCR amplification of modification cassettes containing 
both gentamycin and phleomycin resistance markers 
(kindly provided by Dr. GG van Dooren) 
 
pTetSag4-ACP-cmyc-
DHFR 
Expression vector for T. gondii - containing 
anhydrotetracycline (ATc)-regulatable TetO7Sag4 
promoter for generating C-terminal myc-tagged 
parasite line (Meissner et al., 2001; kindly provided by 
Dr. B Striepen) 
 
ptub-FNR-RFP/sag CAT Expression vector for T. gondii - encoding an 
apicoplast-targeting domain of feredoxin-NADPP+P 
reductase (FNR) fused with RFP (Striepen et al., 2000) 
 
ptub-S9-GFP/sag CAT Expression vector for T. gondii - encoding a 
mitochondrial marker S9 ribosomal protein fused with 
GFP (DeRocher et al., 2000)  
 
pUB30 Y. lipolytica/E. coli shuttle vector (Garofano et al., 
2006) for Yarrowia transformation  
 
pUB38 Y. lipolytica/E. coli shuttle vector used as a template for 
PCR amplification of Yarrowia mitochondrial targeting 
sequence complex I NUAM subunit (Garofano et al., 
2006) 
 
pUB30-NUAM-TgNDH2-
I (AA24) 
For Y. lipolytica transformation –  encoding NUAM 
targeting sequence fused with the 24PthP amino acid of 
TgNDH2-I mature peptide (Lin et al., 2008) 
 
pUB30-NUAM-TgNDH2-
I (AA51) 
For Y. lipolytica transformation –  encoding NUAM 
targeting sequence fused with the 51PstP amino acid of 
TgNDH2-I mature peptide (Lin et al., 2008) 
 
pUB30-TgNDH2-I (FL) For Y. lipolytica transformation – encoding full-length 
TgNDH2-I (Lin et al., 2008) 
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pUB30-NUAM-TgNDH2-
II (AA62) 
For Y. lipolytica transformation – encoding NUAM 
targeting sequence fused with the 62PndP amino acid of 
TgNDH2-II mature peptide (Lin et al., 2008) 
 
pUB30-TgNDH2-II (FL) For Y. lipolytica transformation – encoding full-length 
TgNDH2-II (Lin et al., 2008)   
 
 
2.1.3 Cosmids 
 
PSBLE59 Containing TgNDH2-I entire genome (kindly provided 
by Dr. LD Sibley) 
 
PSBM942 Containing TgNDH2-II entire genome (kindly provided 
by Dr. LD Sibley) 
 
 
2.1.4 Oligonucleotides  
 
Table 2.1 Oligonucleotides used for cosmid recombineering  
Primers Sequences (5’→ 3’) 
coseq2-  TTCAGCGTGATCGTATGGTC 
coseq4- (for sequencing) TGATCTACGTGCAAGCAGATTA 
cosIKO+ TCCGAACGACTCCGTCAATCCTCT 
cosIKO- ACTGAGGATGCAATGCGCGCGGAA 
cosIIKO+ CTCCAAAGACACTGTTTCAAGCTC 
cosIIKO- GTGCACAAATATGTATGTAAACTC 
cosIRT+ ATCCTCGTCGACCAGCAAATGAAG 
cosIRT- TTCGCGGTCCTGCTCGACGCGGCGACA 
cosIIRT+ GCTCGTTGACCTACCGCAACGG 
cosIIRT- ACGTGGGAAACTCTGGATGCATGCTT 
cosIsp- GCCAAGTAGCGACCTGCCTGCTTC 
cosIIsp- TTGATGAAATCGGCGAACTCTGCT 
gen+ (for sequencing) ATCGCAGGTTAATTAGTGGAAGA 
Ico+ ATGGCAGGGCAGTGGCTGCGGCTGCTGGCGGG
GGCCTCTGTGCCTATGCTATACGACTCACTATA
GGGCGAATTGG 
 
Ico- 
 
CGCAAGAAGTTTCACGAACTGCTCCTTTGTCAT
TTGCGTTTGACGCGGCTCCTCGACTACGGCTTC
CATTGGCAAC 
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IIco+ 
 
ATGGCGATGCTCTTCTCCAGCTCAGCAGCAGGC
AGCCTGCCCTCGCGCAGATACGACTCACTATAG
GGCGAATTGG 
 
IIco- 
 
GGCAGGGCTGCGAGTTCGAAGTTGTTCATCACT
TTCTTCCGGATGGCCATCCTCGACTACGGCTTC
CATTGGCAAC 
 
NDH2-Isp+  GAAGGATCGACTGCCTTTGCGCTCT 
NDH2-IIsp+ TCGGCATTCTCTTACTCTCGGTCT 
WT-NDH2-I- TGAACGTCTGCGCCAAGTAGC 
WT-NDH2-II- TACGTCCCCAGCAAACGGCTCC 
 
Table 2.2 Oligonucleotides used for real-time PCR 
Primers  Sequences (5’ → 3’) 
Bag1+ GACCGGTCGCCTCTCAACAGC 
Bag1- CGCGCAAAATAACCGGACACT 
Enolase1+ CGAGGGGTGGCTGAAAAAGTATCC 
Enolase1- CAGCGAAGGCCCACGACAAG 
NDH2-I+ CTCGTCGACCAGCAAATGAAGG 
NDH2-I- TGAACGTCTGCGCCAAGTAGC 
NDH2-II+ GCCGCCAGGGTGGACATTTCAA 
NDH2-II- TACGTCCCCAGCAAACGGCTCC 
Tub+ CGCCACGGCCGCTACCTGACT 
Tub- TACGCGCCTTCCTCTGCACCC 
 
Table 2.3 Oligonucleotides used for split GFP complementation  
Primers Sequences (5’ → 3’) 
GFPsp11O- (for sequencing) TGAGACTGTGTGAAATGCCACA 
GS_seq+ (for sequencing) ACTCGTTCGCCGTCCCTGAC 
(GS)B4B-AvrII+  
[5’phosphate modified] 
[phos]CTAGGGGCTCTGGATCGGGCTCTGGAAG
CC 
 
(GS)B4B-AvrII- 
[5’ phosphate modified] 
 
[phos]CTAGGGCTTCCAGAGCCCGATCCAGAGC
CC 
 
LS(GGGGS)B2BAA-AvrII+  
[5’ phosphate modified] 
 
[phos]CTAGGCTCTCTGGCGGAGGCGGATCTGG
CGGAGGCGGAAGCGCGGCGC 
 
LS(GGGGS)B2BAA-AvrII-  
[5’ phosphate modified] 
[phos]CTAGGCGCCGCGCTTCCGCCTCCGCCAG
ATCCGCCTCCGCCAGAGAGC 
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SG-NDH2-I-AvrII- TACCTAGGCTTGCGTCGGTCGCCGTACACA 
SG-NDH2-I-BamHI+ TAGGATCCAAAATGGCAGGGCAGTGGCTGCG
GT 
 
SG-NDH2-IB399B-AvrII- TACCTAGGCTGCTGCTGAGCCTCGCGCAGCTC
GG 
 
SG-NDH2-IB487B-AvrII- TACCTAGGCTGCTCCTTTGTCATTTGCGTTTG
AC 
 
SG-NDH2-II-AvrII- TACCTAGGGTGGTTGTAATATTCGTGATCC 
SG-NDH2-II-BglII+ TAAGATCTAAAATGGCGATGCTCTTCTCCAGC
TA 
 
SG-SCSβ-AvrII- TACCTAGGCGGCGCCGAAATGTGAAC 
SG-SCSβ-BamHI+ TAGGATCCAAAATGGCGCTCTCAGCCGCT 
TgCox19-AvrII- TACCTAGGCCGGTCTGGCGACCGGAGCGCCC
CT 
 
TgCox19-BglII+ TAAGATCTAAAATGTCTTCGTTGGCGCTTTAC
CAGT 
 
TgCytC420-AvrII- TACCTAGGCGAATCCTTTTCCGAGGACATGAT
GTCA 
 
TgCytC420-BglII+ TAAAGATCTAAAATGGCGCAGAAACCTGGCT
CCTCA 
 
TgCytC750-AvrII- TACCTAGGTTTGTTGGAGGCATCAACAAGGT
ACG 
 
TgCytC750-BglII+   TAAGATCTAAAATGTCGCGTGCTGAACCTGA
CGTC 
 
 
All oligonucleotides used for TgNDH2s and Y. lipolytica cloning are listed in 
Supplementary Table S1 (Lin et al., 2008). 
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2.1.5 Antibodies 
 
Table 2.4 Antibodies used for Western blots (WB) and immunofluorescence assays 
(IFA) 
Antibodies (company) Working dilution (WB; IFA) 
Anti-BAG1 (7E5; Bohne et al., 1994) 
 
IFA 1:500 
Anti-c-myc (clone 9E10; Sigma) WB1:500; IFA 1:250 
Anti-GFP (MBL) WB 1:1000; IFA 1:250 
Anti-mouse-IgG AP conjugate  
(Jackson ImmunoResearch Lab.) 
 
WB1:3000 
Anti-rabbit-IgG Cy2 conjugate  
(Jackson ImmunoResearch Lab.) 
 
IFA 1:300 
Anti-mouse-IgG Cy3 conjugate  
(Jackson ImmunoResearch Lab.) 
 
IFA 1:300 
Anti-mouse-IgG HRP conjugate  
(Jackson ImmunoResearch Lab.) 
 
WB 1:5000 
Anti-rabbit-IgG HRP conjugate  
(Jackson ImmunoResearch Lab.) 
 
WB 1:5000 
Anti-TgNDH2-I (Saleh 2006) IFA 1:300 
FITC-conjugated lectin  
(from Dolichos biflorus; Sigma) 
 
IFA 1:300 
 
2.1.6 Enzymes 
 
Alkaline antarctic phosphatase New England Biolabs  
DNase I Sigma-Aldrich  
Finnzymes Phusion high-fidelity DNA 
Polymerase 
 
Finnzymes 
KOD DNA Polymerase  Novagen 
M-MLV (H minus) Reverse Trancriptase 
RNase, Point Mutant 
 
Promega  
Quick T4 DNA Ligase New England Biolabs  
Restriction Enzymes New England Biolabs  
RNase A Sigma-Aldrich 
Taq DNA Polymerase Roche  
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2.1.7 Kits 
 
BacTiter-Glo Microbial Cell Viability Assay 
 
Promega  
BCA Protein Assay Kit Pierce  
ECL detection reagent Amersham 
GenElute Mammalian Total RNA Kit Sigma 
GenElute Plasmid Mini Prep Kit  Sigma 
GenElute Plasmid Maxi Prep Kit Sigma 
GenElute Mammalian Total RNA Kit Sigma 
PeqGOLD Tissue DNA Mini Kit Peqlab  
QIAGENP P CR Cloning Kit Qiagen 
QIAGEN PCR Purification Kit Qiagen 
Quick Ligation Kit New England Biolabs 
 
2.1.8 Molecular Weight Markers 
 
GeneRuler 100 bp DNA Ladder MBI Fermentas  
GeneRuler 1 kb DNA Ladder MBI Fermentas 
PeqGOLD Protein-Marker IV Peqlab  
Prestained Protein Marker, Broad Range  
(6-175 kDa) 
 
New England Biolabs  
 
2.1.9 Antibiotics 
 
Table 2.5 Working concentration used for selection 
Antibiotic (dissolving solvent; company) Working concentration 
Ampicillin (ddHB2BO; Sigma) 100 µg/ml 
Chloramphenicol (ethanol; Sigma) 20 µg/ml 
Gentamycin (stock solution from Biochrom) 10 µg/ml 
Phleomycin (ddHB2BO; Sigma) 50 µg/ml 
Pyrimethamine (ethanol; Sigma) 1 µM 
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2.1.10 Fluorescent Probes 
 
Table 2.6 Working concentration used for staining ∆ψBmB in T. gondii 
Dye (company) Stock solution Working concentration 
DiOCB6B(3) (Invitrogen) 100 µM in DMSO 5 nM 
JC-1 Mitochondrial 
Membrane Potential 
Assay Kit (Cayman 
Chemical) 
 
100× JC-1  1× JC-1  
Reduced Mitotracker Red 
CM-H2XRos (Invitrogen) 
 
100 mM in DMSO 0.5 µM 
TMEM  (Invitrogen) 100 µM in DMSO 15 nM 
 
2.1.11 Chemicals for Substrates Complementation 
 
Table 2.7 Working concentration used for substrate complementation  
Chemical (company) Stock solution Working concentration 
Atovaquone (Sigma) 5 mM in DMSO 1 µM 
Ascorbate (Sigma) 1 M in Ampuwa HB2BO 1.5 mM 
Digitonin (Sigma) 10 mM in DMSO 2 µM   
Dihydroorotate (Sigma) 10 M in DMSO 10 mM  
Glycerol-3-phosphate 
(Sigma) 
 
1 M in Ampuwa HB2BO 1 mM 
HDQ (kindly provided by  
Dr. W Oettmeier) 
 
20 mM in ethanol 1 µM 
Malate (Sigma) 10 M in Ampuwa HB2BO 10 mM  
Oxaloacetate (Sigma) 10 M in Ampuwa HB2BO 10 mM  
Succinate (Sigma-Alrich) 10 M in Ampuwa HB2BO 10 mM  
Tetramethyl-phenylene- 
diamine (TMPD; Sigma) 
 
100 mM in Ampuwa HB2BO 0.2 mM  
Uracil (Sigma) 1 M in DMSO 250 µM  
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2.1.12 Standard Media and Buffers 
2.1.12.1 Mammalian Culture Media and Reagents 
 
ATP/GSH/Cytomix 12 mg ATP  
15.2 mg glutathione (GSH) 
 in 10 ml cytomix 
 
Cytomix (pH 7.6) 120 mM KCl  
150 µM CaClB2B, 
10 mM KB2BHPOB4B/ KHB2BPOB4B (pH 7.6) 
25 mM HEPES 
2 mM EDTA 
5 mM MgClB2B 
in 1L Ampuwa HB2BO  
(adjust pH with KOH) 
 
1% EDTA/PBS 
 
1% (w/v) EDTA  
in 1× PBS (Biochrom) 
 
10%FCS/DMEM 10% (v/v) FCS  
1% (v/v) Pen/Strep (Biochrom) 
in DMEM (Biochrom) 
 
Freezing medium 20% (v/v) FCS 
20% (v/v) DMSO  
in DMEM 
 
pH shift medium (pH 8.3 at 37ºC) 50 ml 10× DMEM (NaHCOB3B-free) 
5 ml FCS 
5 ml 100× Pen/Strep  
10 ml 1M Tricine (pH 8.2 at 37ºC)  
5 ml NaB2BCOB3B (Biochrom) 
5 ml 100× Glutamix (Gibco) 
in 500 ml Ampuwa sterile HB2BO 
(adjust pH with KOH) 
 
0.25% trypsin/PBS 
 
0.25% (w/v) trypsin in 1× PBS  
 
All chemicals not explicitly listed above were purchased from Biochrom, Gibco or 
Sigma. 
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2.1.12.2 Bacterial Culture Media and Reagents 
 
LB (Luria Broth)  1% (w/v)BactoP PTrypton (Becton Dickinson) 
0.5% (w/v) BactoP Pyeast exact  
0.5% (w/v) NaCl 
in ddHB2BO 
 
LB-plate  
(with antibiotics) 
 
2% (w/v) BactoP PAgar in LB 
(working concentration refers to Table 2.5) 
 
TFB1 (pH 5.8) 100 mM RbCl 
50 mM MnClB2B 
30 mM potassium acetate 
10 mM CaClB2B 
15% (v/v) glycerol 
in ddHB2BO 
 
TFB2  (pH 6.8)  10 mM MOPS  
10 mM RbCl 
75 mM CaClB2B 
15% (v/v) glycerol 
in ddHB2BO 
 
2.1.12.3 Standard Buffers 
 
AP staining solution  0.05% (v/v) BCIP  
0.5% (v/v) NBT 
in substrate solution  
 
BCIP 5% (w/v) 5-bromo-4-chloro-3-indolyl- 
phosphate in ddHB2BO 
 
Blocking solution  5% (w/v) dry skimmed milk power  
0.2% (v/v) Tween 20  
0.2% (w/v)  NaNB3B  
in 1× PBS (pH 7.4) 
 
Buffer P1 (home-made) 50 mM Tris-HCl, pH 8.0 
10 mM EDTA, pH 8.0 
100 µg/ml RNAse A 
in ddHB2BO 
 
Buffer P2 (home-made) 200 mM NaOH 
1% (w/v) SDS 
in ddHB2BO 
 
Buffer P3 (home-made) 3 M potassium acetate (pH 5.5) 
Coomassie staining solution  0.025% (w/v) coomassie brilliant blue G  
30% (v/v) methanol  
10% (v/v) acetic acid  
in ddHB2BO 
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Destaining solution 30% (v/v) methanol 
10% (v/v) acetic acid  
in ddHB2BO 
 
10× DNA loading dye 40% (v/v) glycerol  
1% (w/v) bromophenol blue 
in TE buffer (pH 8.0) 
 
10× Electrode buffer (pH 8.3 - 8.5) 30.3 g Tris 
144.41 Glycine 
10 g SDS  
 in 1L of ddHB2BO  
(adjust pH with glycine) 
 
Elution Buffer (pH 2.8) 
(for affinity purification) 
0.2 M Glycine 
1 mM EGTA  
(adjust pH with 1M Tris, pH 9.84) 
 
Moviol oil  2.4 g Moviol 4-88  
7.81 ml 87% glycerol 
12 ml 0.2 M Tris-HCl, pH 8.5 
 
NBT 1% (w/v) nitrotetrazolium blue chloride 
in ddHB2BO 
 
4% PFA/PBS 4% (w/v) paraformaldehyde in 1× PBS 
 
Resolving gel (10%)  940 µl 0.5 M Tris-HCl (pH 6.8)  
100 µl 10% SDS 
1.67 ml 30% acrylamide/bisacrylamide 
20 µl 10 % (w/v) APS 
10 µl TEMED 
2.27 ml ddHB2BO 
 
5× sample buffer 5.7 ml 87% glycerol   
1 g SDS 
3.125 ml 1 M Tris-HCl (pH 6.8)  
100 µL 0.5 % (w/v) bromophenol blue   
0.25 g DTT  
in 10 ml ddHB2BO 
 
Stacking gel (4.4%) 400 µl 0.5 M Tris-HCl (pH 6.8)  
100 µl 10% (w/v) SDS 
1.45 ml 30% acrylamide/bisacrylamide 
12.5 µl 10% (w/v) APS 
10 µl TEMED 
10 µl 1% (w/v) Bromophenol blue 
400 µl ddHB2BO 
 
Substrate solution  200 ml 10% (v/v) diathamolamine (pH 9.6) 
20 µl 5 mM MgClB2B   
800 ml physiological NaCl (pH 7.4) 
 
50× TAE (pH 8.0) 242 g Tris 
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57.1 ml 98% acetic acid  
100 ml 0.5M EDTA (pH 8.0)  
in 1 L ddHB2BO 
 
10× TBS (pH 7.6) 24.2 g Tris 
80 g NaCl 
in 1 L ddHB2BO 
 
10× TE buffer (pH 8.0) 100 mM Tris  
10 mM EDTA 
in ddHB2BO 
 
0.25% Triton X-100/PBS 0.25% (v/v) Triton X-100  
in 1× PBS 
 
Washing solution  0.05% (v/v) Tween 20  
in 1× TBS (pH 7.4) 
 
2.1.13 Chemicals 
 
Acrylamide/bisacrylamide  
 
Roth 
Adenosine 5’ triphoshpate (ATP) Sigma 
Ammounium peroxodisulfate (APS) Merck 
Ampuwa sterile water  Fresenius kabi 
Diethanolamine Sigma-Alrich 
1,4-Dithiothreit (DTT) Roth 
Glutathione (GSH) Sigma 
Manganese Chloride (MnClB2B) Merck 
Moviol 4-88 reagent  Fluka 
Potassium dihydrogen phosphoate 
(KHB2BPOB4B) 
 
Roth 
Potassium phosphate monobasic 
(KB2BHPOB4B) 
 
Calbiochem 
Rubidium Chloride (RbCl) Sigma-Alrich 
Sodium azide (NaNB3B) Sigma 
TEMED Roth 
Triton X-100 Sigma-Alrich 
Tween 20 Sigma-Alrich 
 
All chemicals not explicitly listed above were purchased from Calbiochem, Merck, 
Roth or Sigma. 
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2.1.14 Apparatus 
 
Acrylamide gel cast Modell Mini Protean II  (BioRad) 
Agarose gel chambers Keutz Labortechnik (Reiskirchen) 
Cell electrophoration system Electro manipulator 600 (BTX) 
Centrifuges Megafuge 2.0 (Heraeus)   
Megafuge 2.0 RS (Heraeus)  
Modell 5417 C (Eppendorf)  
Modell 5417 R (Eppendorf)  
RC-26 Plus (Sorvall-Kendro) 
 
Digital balances BP 221 S (Sartorius)  
LP 6200 S (Sartorius)  
 
Electrophoresis power supply EPS 600 (Amersham Pharmacia Biotech)  
Standard Power Pack P25 (Biometra) 
 
Gel documentation system BioDoc II  (Biometra)  
Gel Electrophoresis  Modell Mini Protean II (BioRad) 
Incubators Heraeus 
Lightcycler Roche 
Luminescent image analyzer Image Reader LAS-4000 (Fujifilm) 
Luminometry Wallac 1420 Multilabel Counter (Perkin Elmer) 
Light microscopy Modell DM IL (Leica)  
pH Meter Modell OV5 (Biometra) 
Photometer Ultraspec 1000 (Pharmacia Biotech)  
Pipette aids Pipetboy acu (IBS Integra Biosciences) 
Pipetus-akku (Herschman Laborgerate) 
 
Pipettes Modell Research (Eppendrof)  
Semi-dry transfer cell Transfer-Blot SD cell (Bio Rad)  
Shaker SM-30 Control (Johanna Otto)  
Thermocycler  Modell T3 (Biometra) 
Thermomixer Modell Compact (Eppendorf) 
Time-lapse microscopy Axiovert 200 M microscopy (Zeiss) 
UV-Crosslinker UVC-500 (Hoefer) 
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2.2 Methods 
2.2.1 Bioinformatics  
The putative T. gondii cytochrome c (TGME49_019750; TGME49_029420) and 
cytochrome c oxidase Cox19 (TGME49_054260) were identified by BLAST searches 
in genomic and/or cDNA sequence data via TUhttp://ToxoDB.orgUT, using amino acid 
sequences of S. cerevisiae Cyc1 (NP_012582) and Cox19 (NP_013082) as queries, 
respectively. The TMHMM Server v. 2.0 was used for prediction of transmembrane 
helices in proteins (TUhttp://www.cbs.dtu.dk/services/TMHMM/UT). Multiple sequence 
alignments were done using the ClustalW program at the EMBL-EBI 
(TUhttp://www.ebi.ac.uk/clustalw/UT). Programs including MitoProt 
(TUhttp://ihg2.helmholtz- muenchen.de/ihg/mitoprot.htmlUT) and SignalP 3.0 Server 
(TUhttp://cbs.dtu.dk /services/SignalP/UT) were used to predict subcellular localisation.  
 
2.2.2 Plasmid Construction 
2.2.2.1. Plasmid Construction for Y. lipolytica Transformation 
Detailed information of plasmid construction for Yarrowia transformation was 
described previously (Lin et al., 2008).  
 
2.2.2.2 Plasmid Construction for Split GFP Complementation 
The complete open reading frames (ORFs) of TgSCS-β and TgNDH2-II were 
amplified from plasmids pTet-sag-SCSb-cmyc-DHFR (Fleige et al., 2008) and pTet-
sag–ndh2-II-cmyc-DHFR (Lin et al., 2008) using Phusion polymerase with the primer 
sets SG-SCSβ-BamHI+ and SG-SCSβ-AvrII-, and SG-NDH2-II-BglII+ and SG-
NDH2-I-AvrII-, respectively. The coding sequences of TgNDH-I, TgNDH2-IB399B and 
TgNDH2-IB487B were amplified from pTet-sag-ndh2-I-cmyc-DHFR (Lin et al., 2008) 
using the sense primer SG-NDH2I-BamH1+ and antisense primers SG-NDH2-I-
AvrII-, SG-NDH2-IB399B-AvrII- and SG-NDH2-IB487B-AvrII-, accordingly. For PCR 
amplifying the ORFs of TgCytC750, TgCytC420 and TgCox19, cDNA of RH strain 
was used as a template. The primer sets used were TgCytC750-BglII+ and 
TgCytC750-AvrII- for TgCytC750; TgCytC420-BglII+ and TgCytC420-AvrII- for 
TgCytC420, and TgCox19-BglII- and TgCox19-AvrII- for TgCox19. All PCR 
fragments were first cloned into pDrive and DNA sequenced. The BglII/AvrII or 
BamHI/AvrII fragments were finally subcloned into pCTG1-10 resulting in a C-
terminal GFP1-10 fusion or into pBTG11 resulting in a C-terminal GFP11 fusion (van 
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Dooren et al., 2008). For some fusion constructs, an additional flexible linker 
consisting of (GS)B4B residues or LS(GGGGS)B2BAA residues (Arai et al., 2001) was 
inserted into the AvrII site of the fusion constructs, which was derived from self-
annealing oligonucleotides from primer sets (GS)B4B-AvrII+/- and LS(GGGGS)B2BAA-
AvrII+/-, respectively. All constructs were verified for correct sequences and 
orientations. All oligonucleotides mentioned above are listed in Table 2.3 in Section 
2.1.4.  
 
2.2.2.3 Gel Purification  
DNA was extracted from agarose gel using QIAGEN PCR Purification Kit according 
to the manufacturer’s protocol. In brief, DNA was resolved on a ~1 % agarose gel 
with 0.5 mg/ml ethidium bromide in 1× TAE. Each of the observed bands was 
visualized and excised with a scalpel under ultraviolet light. Three volumes of Buffer 
QG were added to 1 volume of the excised gel. Gel was completely dissolved by 
shaking at 50ºC for 5-10 min and then mixed thoroughly with 1 gel volume of 
isopropanol. The mixture was applied to a QIAquick spin column placed in a 2-ml 
collection tube. DNA was bound by centrifugation at 13,000 ×g for 1 min and next 
washed with 750 µl of Buffer PE. Finally, DNA was eluted by adding 30 µl of pre-
warmed ddHB2BO to the centre of the column and collected by centrifugation.  
  
2.2.2.4 PCR Cloning 
The purified PCR fragments were subcloned into pDrive vector according to the 
manufacturer’s protocol (QIAGENP P CR Cloning Kit). PCR products were added with 
a molar ratio of 5 times more than pDrive cloning vector (50 ng) for ligation.  
 
2.2.2.5 Restriction Endonuclease Digestion of DNA 
Restriction endonuclease digestion for subcloning was performed in 20 µl ddHB2BO 
containing 2 µg of plasmid DNA, 1× NEB buffer, 1× BSA (optional), and 2 U of 
restriction endonucleases. The reaction mixture was normally incubated at 37ºC (55ºC 
for SfiI; 25ºC for ApaI) for 3 h. For screening clones, reaction was done in a total 
volume of 10 µl ddHB2BO containing 1 µg of plasmid or cosmid DNA, 1× NEB buffer, 
1× BSA (optional), and 1 U of restriction endonucleases. Restriction enzyme digestion 
was normally incubated at 37ºC for 1 h. 
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2.2.2.6 Alkaline Phosphatase Reaction  
Vectors followed by restriction endonuclease digestion (20 µl) were added with 2 µl 
(instead of 4 µl) of 10× alkaline phosphatase buffer, 2 U of alkaline phosphatase, and 
leveled up with ddHB2BO to 40 µl. The reaction was kept at 37ºC for 15 min and 
inactivated at 65ºC for 5 min. 
 
2.2.2.7 Ligation of DNA 
Ligation reaction was performed in a 20-µl reaction volume containing gel-purified 
inserts with a molar ratio of 5 times more than vector (100 ng), 1× ligation buffer and 
1 U of T4 DNA ligase. The ligation reaction was kept at RT (25ºC) for 30 min or 
incubated overnight at 16ºC.  
 
2.2.2.8 Preparation of chemically Competent E. coli Cells 
A single colony of E. coli cell was inoculated into 5 ml LB without antibiotics and 
grown overnight at 37ºC with vigorous shaking. Overnight culture (2 ml) was added 
into 100 ml pre-warmed LB medium and grown at 37°C until an ODB600B of 0.5 was 
reached. The culture was transferred into 50-ml tubes and cooled on ice for 15 min. 
Cells were collected after centrifugation at 4000 ×g for 10 min at 4°C. The cell pellet 
was gently resuspended in 30 ml ice-cold TFB1 buffer and incubated on ice for 30 
min. Cells then were pelleted by centrifugation as described above, resuspended in 4 
ml ice-cold TFB2 buffer, and incubated on ice for another 30 min. Competent cells 
(100 µl) were aliquoted in pre-chilled 1.5-ml tubes and immediately frozen at -80°C. 
 
2.2.2.9 Cell Transformation  
Transformation of plasmid DNA was performed using TOP10 or DH5α chemically 
competent cells. Competent cells were first thawed on ice for 3-5 min. Total amount 
of 5 µl from ligation-reaction mixture was slowly added into the cells without any 
vortexing. Cells were further incubated on ice for 30 min. After that, cells were heat-
shocked in a 42ºC water bath for 45 s followed by 2-min incubation on ice. Nine 
hundred µl of LB was added to the cells and kept shaking at 37ºC for 1 h at 250 rpm. 
Finally cells were plated on an LB-ampicillin agar plate (100 µg/ml ampicillin). For 
white-blue colony selection, 40 µl of X-gal (40 mg/ml) and 40 µl of IPTG (1 M) were 
added onto the plate. Plates were incubated overnight at 37ºC. 
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2.2.2.10 Plasmid Preparation  
2.2.2.10.1 Screening Clones 
The selected single colony was inoculated into 5 ml LB supplemented with antibiotics 
and grown overnight at 37ºC with vigorous shaking. Plasmid DNA was isolated from 
overnight culture (3 ml) using GenElute Plasmid Mini Prep Kit according to the 
manufacturer’s instructions. Purified plasmid DNA was digested with restriction 
endonucleases to screen the expected DNA insert. DNA sequencing was performed in 
commercial company Seqlab (TUwww.seqlab.deUT). Large scale of plasmid preparation 
was purified by GenElute Plasmid Maxi Prep Kit.  
 
2.2.2.10.2 Determination of DNA Concentration 
DNA concentration was determined photometrically and calculated from the 
absorbance at 260 nm as follows: DNA concentration (µg/ml) = absorbance × 50 × 
dilution factor of the measured samples. 
 
2.2.2.10.3 DNA Precipitation 
Dissolved DNA (typically in HB2BO, TE buffer or Tris-HCl, pH 7.5-8.0) was added with 
1/10 volume of 3 M sodium acetate (pH 5.2) and 2.5 volumes of 100% ethanol. The 
sample was mixed by inverting the tube 6 times and incubated at -20ºC for 30 min. 
Supernatant was removed from the tube after centrifugation at 14,000 rpm for 20 min. 
DNA was once with 1 ml of 70% ethanol and centrifuged again. After removing the 
ethanol, DNA pellet was air-dried under laminar flow hood for 5-10 min and 
resuspended with 50 µl of ddHB2BO. Plasmid or cosmid DNA used for electroporation 
was resuspended with 45 µl of cytomix.   
 
2.2.3. Cosmid Recombineering 
2.2.3.1. Preparation of Electrocompetent Cells 
SW103 (λ prophage deficient) E. coli strain was inoculated into 5 ml LB without 
antibiotics and grown overnight at 30ºC with vigorous shaking. Two ml of the 
overnight culture was added into 100 ml pre-warmed (30ºC) LB and grown at 30ºC 
until an ODB600B of 0.4 was reached. The culture was cooled on ice for 20 min swirling 
every 5 min. After that, the culture was transferred into 50-ml tubes and centrifuged at 
4,000 rpm for 10 min at 4°C. The cell pellet was resuspended in 50 ml ice-cold ddHB2BO 
followed by centrifugation as described above. The cell pellet then was sequentially 
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washed once with 50 ml, 20 ml and 3 ml of ice-cold ddHB2BO. Finally the cell pellet was 
resuspended with 600 µl of 10% (v/v) glycerol. Competent cells were aliquoted in ice-
cold 1.5-ml microfuge tubes (50 µl per tube) and frozen immediately at -80°C.  
 
2.2.3.2. Electroporation of Cosmid DNA 
Electrocompetent SW103 cells were thawed on ice for 3-5 min. Cosmid DNA (200 ng) 
was added into the competent cells with slightly stirring by pipette tip and incubated 
on ice for 1 min. Cells were transferred into an ice-cold 2 mm gap cuvette and 
electrophorated at 1.75 kV, 250 Ω, and 25 µF. A total of 1 ml LB was immediately 
added into cuvette and mixed thoroughly with the cells. Subsequently cells were 
transferred from cuvette into a 1.5-ml tube. Cells were shaken at 30°C for 1.5 h. An 
aliquot of 100 µl from the culture was spread onto an agar plate prepared with 
antibiotics (it depends on the vector backbone; ampicillin is used for selection of 
cosmids PSBLE59 and PSBM942). Several colonies were screened for the targeted 
genes by PCR. Selected clones were kept as glycerol stocks at -80°C. 
 
2.2.3.3. Preparation of SW103 containing Cosmid 
Glycerol stock of SW103 containing cosmid was firstly inoculated into 5 ml LB 
supplemented with 100 µg/ml ampicillin and grown overnight at 30ºC with vigorous 
shaking. Two ml of overnight culture was added into 100 ml LB and grown at 30ºC 
until ODB600B reached at 0.4. Induction of expression of recombinant proteins was done 
on 43ºC water bath with a gentle shaking at ~100 rpm for 20 min. Afterwards the 
culture was cooled in wet ice for 20 min swirling every 5 min. Finally competent cells 
were prepared as the same procedures described in Section 2.2.3.1.  
 
2.2.3.4. Cosmid Modification  
Cosmid recombineering was referred to previous published protocol (Lee et al. 2001). 
Modification cassettes containing gentamycin and phleomycin resistance markers 
were amplified from plasmids piBG using primer sets flanking with 50 bp of gene-
specific sequences (TgNDH2s). Primer sets Ico+ and Ico-, and IIco+ and IIco- were 
respectively used for recombineering PSBLE59 and PSBM942 cosmids, as tabulated 
in Section 2.1.4. PCR products were purified and introduced into cells by 
electroporation and selected on plates supplemented with 100 µg/ml ampicillin and 10 
µg/ml gentamycin. Modified cosmids were screened by PCR using primers that 
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amplify the flanking regions of the targeting cassette. Primer pairs used for confirming 
modified cosmids were NDH2-I-sp+/coseq4- and gen+/cosIsp- for PSBLE59, 
designated as primer Set A and B (see Figure 3.3), respectively; and NDH2-II-
sp+/coseq2- (Set A) and gen+/cosIIsp- (Set B) for PSBM942. Selected clones were 
kept as glycerol stocks at -80°C and further confirmed by DNA sequencing.  
 
2.2.3.5. Cosmid DNA Preparation  
A single colony was inoculated into 5 ml LB supplemented with antibiotics and grown 
overnight at 30°C. Overnight culture (3 ml) was pelleted and lysed with 300 µl of 
Buffer P1 containing RNAse A. Then 300 µl of Buffer P2 and P3 was sequentially 
added into the lysate, mixed gently and incubated at RT for 5 min each. The mixture 
was centrifuged at RT for 10 min. Supernatant then was transferred into a new 1.5-ml 
tube and mixed thoroughly with 0.7 volume of isopropanol (630 µl). After that, the 
mixture was incubated on ice for 5 min and the precipitated DNA was pelleted after 
centrifugation at 4ºC for 30 min. The DNA pellet was washed with 1 ml of 70% 
ethanol and centrifuged at RT for 5 min. Finally supernatant was discarded, DNA 
pellet was air-dried and resuspended in 50 µl TE buffer. Cosmid DNA was stored at -
20°C.  
 
2.2.4 Analysis of Gene Expression 
2.2.4.1 Isolation of Genomic DNA  
Extracellular parasites were collected from the supernatant after centrifugation at 34 
×g for 5 min to remove host cell debris. Parasites then were pelleted at 1,314 ×g for 10 
min at RT. Genomic DNA isolation was prepared using PeqGOLD Tissue DNA Mini 
Kit according to the manufacturer’s protocol. 
 
2.2.4.2. Total RNA Isolation 
Total RNA was isolated by using GenElute Mammalian Total RNA Kit according to 
the manufacturer’s protocol. Intracellular parasites were firstly lysed by adding 500 µl 
of lysis solution containing 1% (v/v) of 2-mercaptoethanol. Cell lysates then were 
transferred into a blue filtration column placed in a 2-ml collection tube and 
centrifuged at 14,000 ×g for 2 min. Equal volume of 70 % ethanol (500 µl) were 
added to the filtrate and thoroughly mixed. Next the mixture was transferred into a 
clear binding column and centrifuged at 14,000 ×g for 15 s. Afterwards flow-through 
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was discarded, the column was washed once with 500 µl of Wash solution 1, twice 
with 500 µl of Wash solution 2 containing ethanol, and centrifuged for 15 s each. 
Additional 1-min centrifugation at 14,000 ×g was done to remove residual ethanol 
from the washing solutions. Finally, total RNA was eluted from the column by adding 
50 µl of RNase-free HB2BO and stored at -80ºC until used.  
 
2.2.4.3 Reverse Transcription – Polymerase Chain Reaction (RT-PCR) 
2.2.4.3.1 Synthesis of cDNA 
First-strand cDNA was reverse-transcribed in a 50-µL RNase-free HB2BO reaction 
containing 5 µg of total RNA, 1× M-ML RT buffer, 1 µM oligo(dT) primer, 0.5 mM 
dNTP, and 5 U of M-MLV reverse transcriptase at 37˚C for 1.5 h. The cDNA was 
diluted by adding 100 µl of RNase-free HB2BO and ready for conventional PCR or real-
time PCR. Samples were stored at -20ºC. 
 
2.2.4.3.2 Polymerase Chain Reaction (PCR) 
PCR conditions were adjusted in accordance to following parameters: properties of 
DNA polymerases and templates, Tm of primer sets, and size of the PCR products. In 
general, PCR amplification was performed in a 25-µl reaction for 28-30 cycles. Each 
PCR reaction contained 50-100 ng of DNA, 1 µM of each upstream and downstream 
primer, 0.25 mM dNTP, 1× PCR reaction buffer, and 0.25 U of DNA polymerases. 
The PCR primer sets used are summarized in Section 2.1.4. For PCR cloning, cDNA 
was firstly purified by QIAquick PCR Purification Kit and PCR reaction was done in 
50 µl reaction volume for 25-28 cycles. All PCR products were analyzed on a ~1 % 
agarose gel with ethidium bromide and were visualized under ultraviolet light. In 
order to check the size of the PCR products, GeneRulerP P1kb or 100 bp DNA LadderP 
Pwas run along with the PCR products. 
 
2.2.4.3.3 Real-time PCR 
Real-time PCR was performed using Lightcycler according to the manufacturer’s 
instructions. PCR amplification was carried out using these parameters: 10 min at 
95ºC followed by 40 cycles of denaturation (95ºC, 10 s), annealing (60ºC, 15 s), and 
extension (72ºC, 20 s). All samples were tested for PCR amplification efficiencies as 
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described previously (Lin et al., 2009). Cp values from PCR amplification were used 
for relative quantification. β-tubulin mRNA transcripts were used for normalization.  
 
2.2.4.3.4 Fusion-PCR 
Fusion-PCR amplification was firstly performed in a volume of 50 µl containing 50 ng 
of each purified DNA fragment with 5 cycles of PCR in the absence of primers with 
following parameters: denaturation (98ºC, 10 s), annealing (55ºC, 10 s), and extension 
(72ºC, 30 s). The PCR reaction was continued for another 7 cycles after adding the 
primer sets. 
 
2.2.5 Cell Cultures 
2.2.5.1 Cultivation of Human Foreskin Fibroblasts  
HFF cells were maintained in DMEM supplemented with 10% FCS and 1% Pen/Strep 
at a 5% COB2B humidified atmosphere. Cells were cultivated in a 175 cmP2 Pcell culture 
flask for 10 days to reach a confluent monolayer. Confluent cells then were split to 
lower cell density by re-cultivated in 175 cmP2P, 25 cmP2P (T25) cell culture flasks or 
plates. Cells were split as follows. The culture medium was aspired by suction and 
washed once with 10 ml of 1% EDTA/PBS. Then cells were added with 5 ml of 
0.25% trypsin/PBS and removed most of the solution after tilting the flask several 
times. Monolayer cells were detached after incubation at 37ºC for 1-2 min and 
resuspended with the same culture medium.  
Human osteosarcoma 143B/206 cells, which lack mitochondrial DNA (Jacobson et al., 
1993), and the parental 143B cell line were maintained in DMEM supplemented with 
10% FCS, 1% Pen/Strep, 1% glutamine, sodium pyruvate (110 µg/ml) and uridine (50 
µg/ml). 
 
2.2.5.2 In vitro Cultivation of T. gondii 
Parasites were propagated in HFF cells as previously described (Roos et al., 1994). In 
brief, tachyzoites were inoculated on a confluent HFF monolayer grown on cell 
culture flasks or plates with DMEM supplemented with 1% FCS and 1% Pen/Strep at 
37˚C in a 5% COB2B humidified atmosphere. Extracellular parasites were released from 
lysed host cells after 2-3 days of post-infection. Parasites were maintained by re-
infection.   
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2.2.5.3 In vitro Differentiation of Tachyzoites to Bradyzoites 
Bradyzoite differentiation was induced by alkaline pH-shift (Soete et al., 1994). 
Tachyzoites were freshly released by syringe passage and 3×10P4 Pparasites were 
inoculated onto a confluent HFF monolayer grown on a glass-bottomed 24-well 
imaging plate or plastic plate. Cell cultures were daily changed with a fresh pH-shift 
medium to remove the extracellular parasites and maintain a constant culture pH. 
Bradyzoite differentiation was achieved after 3-day incubation of pH-shift medium 
and the differentiation rate was verified by immunofluorescence assay. 
 
2.2.5.4 Transfection of T. gondii 
Freshly lysed tachyzoites were harvested by scrapping from the HFF (~60% of lysis) 
monolayer and released by syringe passage. The debris of HFF cells was pelleted by 
centrifugation at 34 ×g for 5 min. Supernatant containing the parasites were 
transferred into a new 50-ml tube and centrifuged at 1,314 ×g for 10 min. Parasites 
were washed once with 5 ml cytomix and centrifuged at 1,314 ×g for 10 min. Parasites 
were resuspended in filtered ATP/GSH/cytomix with a final concentration of 3×10P7P 
parasites/ml. A 1.5-ml tube containing linearized plasmid DNA (50 µg of DNA and 50 
U of restriction endonuclease in 50 µl cytomix) was added with 350 µl of parasite 
suspension and gently mixed. Total volume of 400 µl of the mixture was carefully 
transferred into a 2 mm gap cuvette without causing gas bubbles inside and 
electroporation was done by using a BTX electro manipulator 600 with a setting at 1.5 
kV, 25 Ω and 25 µF. After 15-min incubation at RT, the electroporated parasites were 
transferred into a T25 cell culture flask and immediately put under drug selection by 
chloramphenicol or pyrimethamine. Drug selection by phleomycin was done on 
extracelluar parasites for 4 h. Indicated drug concentration is shown in Table 2.5 in 
Section 2.1.9. 
 
2.2.5.5. Generation of Conditional Knock-out Mutants 
Transgenic lines TgNDH2-I and TgNDH2-II each expressing an inducible copy of 
TgNDH2-I or -II were firstly subcloned. Modified cosmids PSBLE59 and PSBM942 
were electroporated into the parental clonal line of myc-tagged TgNDH2-I and 
TgNDH2-II, respectively. After three rounds of drug selection, parasite lines were 
subcloned into 96-well plate and the isolated single plaques were first screened for the 
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disruption of endogenous gene locus by PCR using primer sets of cosIRT+/WT-
NDH2-I- (Set 1), and cosIKO+/- for TgNDH2-I (Set 2);  and cosIIRT+/WT-NDH2-I- 
(Set 1) and cosIIKO+/- (Set 2) for TgNDH2-II, respectively. Restriction digestion and 
RT-PCR and were further applied to the selected clones to confirm the knock-out 
pattern. Primer pairs used for RT-PCR analysis were as follows: cosIRT+/ - for 
TgNDH2-I; and cosIIRT+/- for TgNDH2-II.  
 
2.2.5.6. Cloning of Transgenic Lines  
Medium in confluent HFF monolayer grown on 96-well plates was changed with 
DMEM supplemented with 1% FCS, 1% Pen/Strep and selection drugs (100 µl per 
well). Extracellular parasites were harvested as described in Section 2.2.5.4. Parasites 
were counted and diluted to 100 parasites per ml. One hundred µl was added into each 
well in the first and seventh vertical columns of a 96-well plate. Serial dilution was 
started from left to right by using a multi-channel pipetor. The parasites were mixed 
well by pipetting several times and were transferred 100 µl into next column. The 
medium was discarded after mixing column 6 and 12. The plates were incubated for 7 
days without disturbing the cultures. Individual wells observed with a single plaque 
were marked and parasites of these clones were transferred into T25 flasks.  
For subcloning the knock-out parasites, single plaques obtained on the 96-well plates 
were transferred into 12-well plates. After 5-6 days, all the clones after infecting 24-
well plates, were harvested for genomic DNA isolation and subjected to PCR for 
knock-out screening. 
 
2.2.5.7 Cryopreservation of T. gondii  
Intracellular parasites were detached as described in Section 2.2.5.1. Detached cells 
were suspended in 10 ml of 10%FCS/DMEM and centrifuged at 400 ×g for 5 min. 
Supernatants then were discarded and the cell pellet was added with 1 ml of ice-cold 
10%FCS/DMEM and quickly mixed with 1 ml of freezing medium. Cells (1 ml) were 
aliquoted in 2-ml cryotubes and kept in liquid nitrogen for long-term storage. For re-
cultivating frozen cells, a cryotube was thawed in a 37ºC water bath and the cells were 
immediately transferred into a cell culture flask freshly changed with 1%FCS/DMEM. 
Cells were incubated at 37ºC in a 5% COB2B humidified atmosphere and replaced with 
new medium after 12 h to remove the residual DMSO. 
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2.2.5.8 Immunofluorescence Assay  
Samples were firstly fixed with 500 µl of 4% PFA/PBS and permeabilized with 500 µl 
of 0.25% Triton X-100/PBS for 15 min each. After blocking with 300 µl of 1% 
BSA/PBS for 1 h, samples were incubated with primary antibodies followed by 
secondary antibodies for 1 h each. Working concentration of staining solution is 
summarized in Table 2.4 in Section 2.1.5. 
 
2.2.5.9 Detection of ∆Ψm  
The T. gondii ∆Ψm was monitored after staining with fluorophores Mitotracker or 
DiOCB6B(3) as described previously (Lin et al., 2009). Working concentration of 
staining solution is summarized in Table 2.5 in Section 2.1.10.  
 
2.2.5.10 Determination of Intracellular ATP Level  
Parasitic ATP level was determined by using the BacTiter-Glo Microbial Cell 
Viability assay. Preparation, measurement and quantification of intracellular ATP 
level were performed as described previously (Lin et al., 2009).  
 
2.2.5.11 Time-lapse Microscopy 
Live imaging of T. gondii ∆Ψm was performed with an inverted Zeiss Axiovert 200 M 
microscopy equipped with a XL-3 incubator and a heating unit (PeCon). Images were 
captured by an AxioCam MRm camera and processed with Axiovision 4.6.3 software. 
All live imaging experiments were performed on a black glass-bottomed 24-well 
imaging plate and kept at 37°C. In brief, confluent HFF monolayer seeded on an 
imaging plate were 16-18 h post-infected with 2-3×10P5P parasites per well. After 
DiOCB6B(3) staining, the plate was transferred into the humidified chamber and drugs 
were added to the wells at the indicated concentrations.  
 
2.2.5.12 Drug Treatment 
Parasites (3-5×10P5P) were inoculated onto confluent HFF monolayer on a 24-well plate 
in correspondent to different time intervals. Drugs were added with the indicated 
concentrations and time intervals.  
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2.2.5.13 Cell Count 
Parasites were 5-fold diluted with 1× PBS and counted using a hemocytometer. 
Parasites per ml = (average counted numbers × 5 × 10P4P)/ml. 
 
2.2.5.14 Statistical Method 
Statistical analysis was performed by Student’s t test. Differences were considered 
statistically significant when p values were less that of 0.05. 
 
2.2.6. Analysis of Protein Expression   
2.2.6.1. Growth of E. coli Expression Cultures 
A selected positive colony was inoculated into 5 ml LB supplemented with 100 µg/ml 
ampicillin and 25 µg/ml chloramphenicol and grown overnight at 37ºC with vigorous 
shaking. One ml of overnight cultures was resuspended in 30 ml of the same pre-
warmed culture medium and grown at 37ºC until an ODB600 Bof 0.6 was reached. Protein 
expression was induced for 1 h by adding IPTG at a final concentration of 1 mM. Cell 
cultures were centrifuged at 4,500 ×g for 15 min at 4ºC and cell pellet was stored at -
20ºC.  
 
2.2.6.2 Growth of Y. lipolytica Cultures 
The protocol of transformation and preparation of mitochondrial membranes was 
described previously (Eschemann et al., 2005; Lin et al., 2008). 
 
2.2.6.3 Protein Extraction 
Protein fractionation for transgenic line TgATPase-β is described in detail in Lin et al., 
2009. For extraction of recombinant protein expressed in E. coli, the harvested cell 
pellet was resuspended in buffer B (pH 8.0; 50 ml per gram wet weight) containing 
100 mM NaHB2BPOB4B, 10 mM Tris-HCl, 8 M urea. The cells were lysed by vortexing 
and stirred by a rotary at 4ºC for 1 h. Supernatant (soluble protein) was collected after 
centrifugation at 8,000 ×g for 20 min at 4ºC. Proteins were loaded with 2× sample 
buffer ready for SDS-PAGE analysis.  
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2.2.6.4 Western Blot analysis  
2.2.6.4.1 Quantification of Protein Concentration 
Protein concentration was determined by BCA protein assay kit according to the 
manufacturer’s protocol.  
 
2.2.6.4.2 Sodium Dodecyl Sulphate – Polyarcylamide Gel Electrophoresis (SDS-
PAGE) 
Separation of proteins was performed by SDS-PAGE. The acrylamide gel cast was set 
up by laying two spacers sandwiched between two rectangular glass plates. Separating 
gel (10% or 12.5%) was pipetted into the space. Upon the polymerization of the 
separating gel, a comb was inserted in the sandwich plates. Stacking gel (4.4%) was 
filled on top of separating gel and waited for solidifying. Equal amount of protein 
samples were mixed with 2× sample buffer and were boiled for 5 min. In the presence 
of 1× electrode buffer, electrophoresis was performed with constant current 0.3 mA.  
 
2.2.6.4.3 Electroblotting of SDS-PAGE 
The polyacrylamide gel was electroblotted using a semidry blot system onto a 
nitrocellulose membrane assembled in the following order: starting at anode direction 
with 6 Whatman filter papers soaked with 0.3 mM Tris-HCl (pH 10.4) and 20% 
methanol; 3 Whatman filter papers soaked with 25 mM Tris-HCl (pH 10.4) and 20% 
methanol; Hybond nitrocellulose membrane (Amersham Biosciences); SDS-PAGE gel 
and 9 Whatman filter papers soaked with 40 mM 6-aminocapronic acid (pH 7.6) and 
20% methanol followed by cathode direction. Proteins were transferred at RT with 
constant current 0.3 mA for 1.5 h. 
 
2.2.6.4.4 Blocking, Washing and Antibody Incubation  
The electroblotted nitrocellulose membrane was first incubated with blocking solution 
at RT for 1 h to reduce non-specific binding of antibody. After the blocking step, the 
membrane was washed once with washing solution for 5 min. Bound proteins on 
membrane was probed with primary antibody overnight at 4ºC. On the second day, 
membrane was washed for 30 min and washing solution was changed every 5 min. 
Next, the membrane was incubated with secondary antibody at RT for 1.5 h. The 
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membrane finally was washed again as described above. The working dilution and 
sources of antibodies are summarized in Table 2.4 in Section 2.1.5. 
2.2.6.4.5 Affinity Purification of Polyclonal Antibodies 
His-tagged recombinant proteins (~50 µg) were resolved by SDS-PAGE and 
transferred onto nitrocellulose membranes. Protein expression was visualized by 
Ponceau S staining and the membrane strip containing the expected protein was cut 
out. The membrane strip was blocked with 5% (w/v) skimmed milk at RT for 1 h and 
incubated overnight with 2 ml of 0.1% Trition X-100/PBS containing 40 µl of raised 
serum at 4ºC. On the next day, the membrane strip was washed 4 times with 0.1% 
Triton X-100/PBS every 5 min. Afterwards the membrane strip was incubated with 
150 mM NaCl at RT for 20 min and washed as described above. The membrane strip 
then was put into a 2-ml tube and sequentially changed with 900 µl elution buffer (pH 
3.5, pH 3.0 and pH 2.5) at RT for 10 min each. Finally each elution fraction was 
diluted to 1:300 by adding 100 µl of 10× PBS, 10 µl of 2% sodium azide (0.02%), and 
100 µl of 10% BSA. 
 
2.2.6.4.6 Protein Detection  
Methods including ECL chemiluminescent detection and alkaline phosphatase (AP) 
staining were used for membrane development. For ECL detection, an equal volume 
of detection solution 1 and 2 were mixed. The washed membrane was drained with the 
mixtures at RT for 1 min. The chemiluminescent signal was recorded by Image 
Reader. While using AP staining, the washed membrane was first incubated with 10 
ml pre-warmed substrate solution at RT for 2 min, followed by 10 ml pre-warmed AP 
staining solution containing BCIP and NBT.  
 
2.2.6.5 Kinetic Measurements 
Measurement and analysis of enzymatic parameters are described in Lin et al., 2008.
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CHAPTER III  
Results 
 
3.1 Biochemical Characterization of TgNDH2s as Drug Targets for HDQ 
 
Results of this section have been described previously (Lin et al., 2008; see Appendix I). A summary 
of the findings is depicted as follows. 
 
The quinolone-like compound HDQ, known as a high affinity inhibitor for the yeast Y. 
lipolytica NDH2 (Eschemann et al., 2005), has been shown to effectively inhibit the 
replication rate of T. gondii in vitro (Saleh et al., 2007). Thus, it is crucial to 
biochemically characterize T. gondii NDH2s to reveal whether these two isoforms, 
TgNDH2-I and TgNDH2-II, are indeed enzyme targets of HDQ. Given the fact that 
both isoforms of TgNDH2s are constitutively co-expressed in tachyzoite and 
bradyzoite stages, a direct biochemistry analysis of individual enzyme parameters for 
TgNDH2s was instead performed on recombinant proteins by using Y. lipolytica as a 
surrogate model. A Y. lipolytica NDH deletion strain was used to heterologously 
express both enzymes fused with a Yarrowia mitochondrial NUAM import protein. 
Both TgNDH2-I and TgNDH2-II were able to display oxidoreductase activities by 
using NADH and n-decylubiquinone (DBQ) as substrates. Additionally, TgNDH2-I 
could rescue the loss of complex I activity, implying that TgNDH2-I is functionally 
expressed in the yeast as an internal enzyme. Furthermore, TgNDH2-I activity was 
effectively inhibited by HDQ with an ICB50B in the nanomolar range, indicating that 
HDQ is a high affinity inhibitor for TgNDH2-I. Steady-state kinetics are in accordance 
with a ping-pong reaction mechanism for TgNDH2-I. Moreover, the mode of 
inhibition of HDQ on TgNDH2-I was analyzed indicating that HDQ is a non-
competitive inhibitor for the NADH-binding site. Further studies on inhibition kinetics 
of the quinolone-like compounds showed that the derivatives with longer alkyl chains, 
such as CB12B (HDQ) and CB14B, are high affinity inhibitors for TgNDH2-I, whereas the 
derivatives with shorter side chains, CB5B and CB6,B yielded higher ICB50B values in the 
micromolar ranges. Collectively, this study provides evidence that type II NADH 
dehydrogenase isoform I is a target enzyme of HDQ in T. gondii.  
 
    Page 54   
Chapter III Results 
3.2 Physiological Consequences of TgNDH2s Inhibition in T. gondii 
 
Results for this section have been described previously (Lin et al., 2009; see Appendix II). A summary 
of the findings is depicted as follows.  
 
The physiological influences of TgNDH2s inhibition on mitochondrial functions were 
explored in this study,  particularly focusing on the subject of oxidative 
phosphorylation. Firstly the impact of high affinity TgNDH2 inhibitor HDQ (Lin et al., 
2008; see Section 3.1) on ∆Ψm in T. gondii was determined by using the cationic 
fluorescent probes Mitotracker and DiOCB6B(3). Observations assayed by both dyes on 
intracellular parasites being exposed to HDQ showed significantly depolarization of 
∆Ψm in T. gondii, implying that the interferences of TgNDH2 activity attributed to 
HDQ inhibition directly affect oxidative phosphorylation. Intriguingly, real-time 
imaging revealed that intracellular parasites challenged by HDQ at nanomolar 
concentrations led to a dramatically collapse of ∆Ψm within minutes. Additionally, the 
collapse of ∆Ψm mediated by HDQ was decreased in the presence of FB0B-ATPase 
inhibitor oligomycin, suggesting that T. gondii may possess a conventional-like FB0B-
ATPase that can be inhibited by oligomycin. As a consequence, proton translocation 
was prevented from entering the mitochondrial matrix and thereby ∆Ψm was able to 
be stabilized. Following that, subcellular fractionation of the lysates from a transgenic 
line expressing an epitope-tagged TgATPase-β, a subunit of FB1B-ATPase, revealed that 
TgATPase-β was explicitly found on membrane fraction, indicating a mitochondrial-
associated FB1B-ATPase in T. gondii. This finding suggests that FB0BFB1B-ATPase in T. 
gondii is conventional-like instead of possessing a soluble FB1B-ATPase as proposed in 
P.  falciparum (Painter et al., 2007). The influence of HDQ on intracellular ATP level 
was further assessed. Intracellular parasites treated with HDQ for 1 h showed a 
significant ATP depletion of 30%, which increased to 70% after 24 h. Taken together, 
these data strongly indicate that HDQ inhibition leads a fast collapse of ∆Ψm and 
eventually results in ATP depletion.  
 
Moreover, the mode of inhibitory actions of HDQ and complex III inhibitor 
atovaquone were compared. HDQ-mediated but not atovaquone-mediated ∆Ψm 
depolarization was stabilized in the presence of excess substrates for the 
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dehydrogenases including succinate dehydrogenase, malate:ubiquinone 
oxidoreductase and dihydroorotate dehydrogenase. These enzymes are localized in the 
respiratory chain upstream of complex III, implying that additional electrons 
contributed from the oxidoreductase activities exerted on these dehydrogenases can 
feed into the ubiquinol pool and partly compensate the HDQ inhibitory effect on 
TgNDH2, preventing a collapse of ∆Ψm. Finally, the long-term HDQ treatment on 
tachyzoites was examined showing that bradyzoite differentiation was induced as 
verified by quantitative RT-PCR. Interestingly, bradyzoites induced by alkaline pH-
shift were detected with a lower percentage of positive-∆Ψm staining, suggesting that 
the importance of oxidation phosphorylation in bradyzoites is different from that in 
tachyzoites.  
 
3.3 Functional Analysis of TgNDH2s 
3.3.1 Elucidating the Orientations of Inner Mitochondrial Membrane-
associated TgNDH2s 
3.3.1.1 TgNDH2-II is an Internal Enzyme 
 
To investigate the orientations of both inner mitochondrial membrane-associated 
TgNDH2s, engineered self-assembling split GFP complementation was used 
(Cabantous et al., 2005). In this approach, C-terminal fragment β-strand 1-10 of GFP 
(GFP1-10) and β-strand 11 of GFP (GFP11) were expressed separately. When both 
molecules are localized to the same compartment, these two engineered GFP 
fragments are able to reconstitute GFP folding and fluoresce. A transgenic parasite 
line expressing a mitochondrial matrix protein TgSCS-β fused with GFP1-10 
(TgSCSβ-GFP1-10) was first generated and the correct mitochondrial targeting was 
verified by co-localization with Mitotracker as illustrated in Fig. 3.1A. To test whether 
TgNDH2-GFP11 fusions are oriented as internal forms, constructs TgNDH2-I-GFP11 
and TgNDH2-II-GFP11 were transfected into TgSCSβ-GFP1-10 line. Living parasites 
from TgSCSβ-GFP1-10 line transfected with TgNDH2-II-GFP11, but not that with 
TgNDH2-I-GFP11, were able to fluoresce and revealed a typical tubular 
mitochondrial pattern under time-lapse microscopic observation, indicating that the 
two C-terminal GFP fragments contributed from TgSCS-β and TgNDH2-II closely 
interacted and reconstituted a functional GFP molecule resulting in fluorescence (Fig. 
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3.1B). This observation was confirmed on fixed samples (Fig. 3.1C). To further 
demonstrate that the fluorescence observed in parasites is indeed due to the interaction 
of TgSCS-β and TgNDH2-II, individual parasite lines TgSCSβ-GFP1-10, TgNDH2-I-
GFP11 and TgNDH-II-GFP11 were monitored. These parasites by themselves were 
unable to fluoresce (Fig. 3.1D). Thus, this finding suggests TgNDH2-II possessing an 
internal orientation that interacts with mitochondrial matrix protein TgSCS-β and 
reconstitutes GFP fluorescence.  
 
3.3.1.2 TgNDH2-I is also an Internal Enzyme 
 
One possible reason that TgSCS-β-GFP1-10 line transfected with TgNDH2-I-GFP11 
did not fluoresce can be attributed to the inaccessibility of GFP11 that hinders a 
correct folding with GFP1-10. The possibility of mitochondrial mis-targeting of 
TgNDH2-I-GFP11 construct was ruled out, since the localization of GFP11 fusion 
protein at mitochondria was confirmed by IFA (Fig. 3.2A). Interestingly, a previous 
study has predicted that type II NADH dehydrogenase in P. falciparum might possess 
an amphipathic helix C-terminus which penetrates into the lipid bilayer (Fisher et al., 
2007). If this is similar in T. gondii, the internal inner mitochondrial membrane 
proteins with C-terminal GFP11 fusion would be limited by split GFP 
complementation approach by interacting with a mitochondrial matrix protein. To 
preclude this possibility, we generated two truncated constructs TgNDH2-IB399B-GFP11 
and TgNDH2-IB487B-GFP11, where hydrophilic C-termini were fused with GFP11 (Fig. 
3.2B). In addition, two constructs TgNDH2-I-GS-GFP11 and TgNDH2-I-LS-GFP11 
(Fig 3.2B) were generated, which were fused with GFP11 domain with extended 
linkers to prevent self-aggregation or to optimize the orientation of the fusions in 
space that brings GFP fragments into close proximity (Remy and Michnick, 2004). 
The constructs were transfected into TgSCS-β line and tested whether mitochondrial 
GFP fluorescence was observed. Strikingly, TgSCS-β line transfected with TgNDH2-
IB399B-GFP11B Band TgNDH2-IB487B-GFP11 both resulted in GFP fluorescence as shown in 
fixed samples (Fig. 3.2C) and confirmed in living parasites (Fig. 3.2D). In contrast, 
TgNDH2-I-GFP11 even fused with additional linkers did not reveal fluorescence. 
Collectively, these data indicate that C-terminal GFP11 of truncated TgNDH2-I 
constructs were able to closely interact with TgSCS-β to reconstitute the GFP 
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molecules, suggesting an internal version of type II NADH dehydrogenase isoform I 
that might have a lipid bilayer oriented C-terminus.  
 
To further exclude that TgNDH2-I acts as an external enzyme, identifying a protein 
localized at the intermembrane space was prioritized. By using sequences of Cyc1 and 
Cox19 from S. cerevisiae as queries, which are well-known to be localized at 
intermembrane space in S. cerevisiae (Lutz et al., 2003), several putative proteins 
including cytochrome c (TGME49_019750, E-value: 5×eP-30P; TGME49_029420, E-
value: 1×eP-12P) and Cox19 (TGME49_054260; E-value: 4×eP-11P) in T. gondii were 
predicted with high E-value. Parasite lines expressing each of putative cytochrome c 
(TgCytC750-GFP1-10; TgCytC420-GFP1-10) and Cox19 (TgCox19-GFP1-10) were 
generated. All constructs were fused with GFP1-10. Eventually parasite line 
TgCytC750-LS-GFP1-10, which includes an additional linker LS(GGGGS)B2BAA 
between the encoding protein and GFP1-10, was targeted to the mitochondrion as 
detected by IFA (Fig. 3.3A). Construct TgNDH2-I-GFP11 was transfected into this 
line. As expected, resulting parasites were unable to fluoresce in fixed samples (Fig. 
3.3B), suggesting TgNDH2-I does not interact with intermembrane space protein 
TgCytC750 and is thus not an external enzyme. 
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Figure 3.1 TgNDH2-II is oriented internally at inner mitochondrial membrane. (A) 
Mitochondrial localization of TgSCSβ-GFP1-10 fusion was detected by IFA using 
anti-GFP antibody and confirmed by co-localization with Mitotracker in fixed samples. 
(B) TgNDH2-II-GFP11 transfected in TgSCSβ-GFP1-10 line results GFP 
fluorescence in living parasites. TgSCSβ-GFP1-10 line was stably transfected with 
TgNDH2-I-GFP1-10 (upper panel) and TgNDH2-II-GFP11 (lower panel). Living 
parasites from each line were observed under time-lapse microscopy. (C) Parasites 
from TgSCSβ-GFP1-10 line being transfected with TgNDH2-II-GFP11 were co-
localized with Mitotracker in fixed sample. (D) Individual living parasites from 
TgSCSβ-GFP1-10, TgNDH2-I-GFP11 or TgNDH2-II-GFP11 line did not reveal GFP 
fluorescence. Scale bar, 5 µm. 
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Figure 3.2 TgNDH2-I is oriented internally at inner mitochondrial membrane. (A) 
Mitochondrial localization of TgND2H-I-GFP11 fusion was detected by IFA using 
affinity-purified anti-TgNDH2-I antibody. (B) Schematic diagrams depicting the 
truncated constructs TgNDH2-IB399B-GFP11 and TgNDH2-IB487B-GFP11, and the 
constructs with additional amino acid residues (GS)B4B and LS(GGGGS)B4BAA linking 
the C-terminus of TgNDH2-I and GFP11 fragment. (C) Mitochondrial localization of 
the parasites from TgSCSβ-GFP1-10 line being transfected with TgNDH2-IB399B-GFP11 
and TgNDH2-IB487B-GFP11 were verified with the co-localization with Mitotracker in 
fixed samples and (D) in living cultures. Scale bar, 5 µm. 
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Figure 3.3 TgNDH2-I is not an external enzyme. (A) TgCytoC750-GFP1-10 fusion 
was localized at mitochondria. Parasites were analyzed by IFA by staining with anti-
GFP antibody. (B) TgCytoC750-GFP1-10 line transfected with TgNDH2-I-GFP11 did 
not fluoresce. Scale bar, 5 µm. 
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3.3.2 Phenotypic Analysis of TgNDH2s Depletion Mutants 
3.3.2.1 Conditional TgNDH2-I and TgNDH2-II Knock-out Mutants achieved by a  
cosmid-based Approach 
 
To study the phenotypes of parasites which lack one of the TgNDH2s, a logical 
strategy is to generate conditional TgNDH2s knock-out mutants (Meissner et al., 
2001), given the possibility that loss of either isoform of TgNDH2s might be 
deleterious for the parasites. Available approaches of gene disruption based on 
homologous recombination are not very efficient (Striepen and Soldati, 2007) due to 
the high frequency of non-homologous recombination. Therefore, a new approach by 
using long flanking sequences from cosmid (~ 40 kb) was applied to increase the 
frequency of homologous recombination (Brooks et al., 2009). Fig. 3.4A has outlined 
the scheme of the adapted recombineering (Lee et al., 2001) for cosmid modification 
by introducing a selection cassette that enables gene deletions. Cosmid clones 
PSBLE59 and PSBM942 including TgNDH2 genomic region were identified (via 
TUwww.toxoDBUT). Modified cosmids PSBLE59 and PSBM942 were achieved and 
verified by PCR (Fig. 3.4B), and the insertion sites flanking the cassettes were 
confirmed by sequencing. To generate conditional knock-out mutants, the modified 
cosmids PSBLE59 and PSBM942 then were respectively transfected into myc-tagged 
TgNDH2-I and TgNDH2-II lines, which encode an additional copy of the target gene 
regulated by an ATc-dependent transactivator promoter (Meissner et al., 2001). Clonal 
lines were tested for successful gene displacements by PCR, as shown in Fig. 3.5B. 
Representative knock-out clones compared to wild-type controls were detected with 
the expected PCR product sizes and further confirmed by restriction digestion on PCR 
products (Fig. 3.5C). Specific restriction site located at selection cassette or at targeted 
TgNDH2s genes were used to confirm the disruption of endogenous gene loci. 
Additionally, gene disruptions of TgNDH2s in depletion mutants (designated as 
∆TgNDH2-I and ∆TgNDH2-II) at mRNA transcripts were confirmed by RT-PCR 
analysis (Fig. 3.5D).  
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Figure 3.4 Cosmid modification by recombineering. (A) Schematic diagram of cosmid 
modification. Cosmids PSBLE59 and PSBM942 were modified by lambda Red-
mediated homologous recombination in SW103 using PCR products containing a 
modification cassette with both gentamycin and phleomycin resistance markers. The 
primers used for PCR amplification flank with 50 bp of homology to the target genes 
TgNDH2s (targeting TgNDH2-I in PSBLE59 and TgNDH2-II in PSBM942) for site-
directed recombination. (B) PCR amplification for verifying cosmid modification. 
Isolated cosmid DNA from a representative clone was subjected to PCR assay using 
two primer sets (Set A, primers PA+/-; Set B, primers PB+/-). Resistance markers: 
GENT, gentamycin; BLE, phleomycin; and AMP, ampicillin. P, parental cosmid; M: 
modified cosmid. 
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Figure 3.5 Generation of conditional knock-out mutants for TgNDH2s. (A) Schematic 
diagram describing a single homologous recombination event in Toxoplasma genome 
that allows the deletion of the endogenous copies of each targeted TgNDH2 gene by 
using long flanking sequences of modified cosmid. (B) Representative knock-out 
clones for TgNDH2-I (24 out of 35 are positive) and TgNDH2-II (38 out of 51 are 
positive). (C) Analysis of knock-out mutant by PCR and restriction digestion in a 
representative clone. Genomic DNA samples from the representative clones were 
assayed by PCR using primer Set 1 and 2. PCR products amplified by using primer 
Set 2 [P2+/- shown in (A)] were analyzed by restriction digestion. (D) Analysis of 
knock-out mutants by RT-PCR. cDNA samples from the representative knock-out 
clones were subjected to PCR amplification. β-tubulin was used as an internal control. 
All analysis includes samples (genomic DNA or cDNA) from wild-type strain. KO, 
knock-out; WT, wild-type. 
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3.3.2.2 TgNDH2-I and TgNDH2-II are non-essential for T. gondii Replication  
 
Having confirmed the disruption of the endogenous gene locus in each conditional 
knock-out mutant (∆TgNDH2-I and ∆TgNDH2-II, the tetracycline-inducible 
transactivator system was first tested in these parasites. A representative clonal line 
from ∆TgNDH2-I and ∆TgNDH2-II was cultivated either in the presence or absence 
of ATc (±ATc) for 72 h, and the exogenous copies of myc-tagged TgNDH2-I and 
TgNDH2-II were effectively suppressed as shown in Fig. 3.6A detected by IFA. Next, 
the growth rates of ∆TgNDH2-I and ∆TgNDH2-II parasites ± ATc were compared 
after two rounds of passages in order to further dilute the residual expression of 
TgNDH2s from the additional ectopic copies (Fig. 3.6B). Additionally, the growth 
rates of the parental myc-tagged TgNDH2-I and TgNDH2–II parasites ± ATc were 
also determined for comparison. These findings showed that the depletion of either 
TgNDH2-I (Fig. 3.6B, left panel) or TgNDH2-II (Fig. 3.6B, right panel) did not affect 
the intracellular replication rate, suggesting that either TgNDH2-I or TgNDH2–II is 
non-essential for parasite growth.  
 
3.3.2.3 TgNDH2-I or TgNDH2-II Depletion does not affect mRNA Transcripts of 
the intact Isoform 
 
In order to investigate whether the depletion of either TgNDH2-I or TgNDH2-II 
affects the mRNA transcript levels of the intact isoform, the steady-state mRNA 
transcript levels of TgNDH2-II in ∆TgNDH2-I and its parental myc-tagged TgNDH2-
I parasites, and TgNDH2-I in ∆TgNDH2-II and its parental myc-tagged TgNDH2-II 
parasites were compared ± ATc and quantified by real-time RT-PCR. These data 
revealed that the relative mRNA transcript levels of TgNDH2-II in ∆TgNDH2-I, and 
TgNDH2-I in ∆TgNDH2-II were unchanged (~ 1–1.4 fold of induction ± ATc) when 
compared to their parental controls (Fig. 3.7), indicating the depletion of one TgNDH2 
isoform does not significantly affect the mRNA transcript level of the intact isoform.  
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Figure 3.6 TgNDH2-I and TgNDH2-II depletion mutants display unaltered growth 
rates. (A) Functional ATc-regulated repression of myc-tagged TgNDH2-I and 
TgNDH2-II. Conditional ∆TgNDH2-I and ∆TgNDH2-II parasites were cultivated 
either in the presence or absence of ATc (± ATc) at a final concentration of 1 µM for 
72 h. Expression levels of exogenous copies of myc-tagged TgNDH2-I and TgNDH2-
II were analyzed by IFA using anti-myc antibody. (B) Comparison of the growth rates 
of ∆TgNDH2-I and ∆TgNDH2-II. ∆TgNDH2-I (left panel) and ∆TgNDH2-II (right 
panel) parasites and their parental controls were grown two rounds (± ATc). Parasites 
(~1×10P5P) from each clonal line were inoculated onto HFF confluent monolayer ± ATc. 
Duplicate samples were fixed after 24 h and the average number of tachyzoites per 
vacuole was determined. At least 100 vacuoles were examined for each sample. 
Results were expressed as means ± S.D. from a representative experiment, N=3. 
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Figure 3.7 Quantitative RT-PCR for assaying mRNA transcripts of (A) TgNDH2-II in 
∆TgNDH-I, and (B) TgNDH2-I in ∆TgNDH-II conditional knock-out mutants. cDNA 
samples from parental and ∆TgNDHs parasites cultivated ± ATc were subjected to 
real-time PCR. β-tubulin was used as an internal control. Results are expressed as 
means ± S.D. of the duplicate samples from a representative experiment.  
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3.3.2.4 TgNDH2-I or TgNDH2-II Depletion does not affect Extracellular Viability 
 
The effects of either TgNDH2-I or TgNDH2-II depletion on the parasite’s 
extracellular viability were further examined. Freshly released extracellular parasites 
from ∆TgNDH2-I and ∆TgNDH2-II, and the parental myc-tagged TgNDH2-I and 
TgNDH2-II lines cultivated ± ATc were immediately infected on HFF confluent 
monolayer ± ATc at 0 h or infected at 7 h that parasites were completely incubated 
without host cells. Samples were fixed after 24 h post-infection. Extracellular viability 
of the parasites was assessed by comparing the infectivity of parasites at 7 h after 
normalization with that at 0 h. As shown in Fig. 3.8, ∆TgNDH2-I or ∆TgNDH2-II 
mutant and their parental controls infected at 7 h were observed with unaltered 
extracellular viability ± ATc (~75-85%), implying that either TgNDH2-I or TgNDH2-
II does not play an important role in maintaining extracellular viability. 
 
3.3.2.5 TgNDH2-I Depletion Mutant is less sensitive to HDQ Treatment 
 
Since HDQ acts as a high affinity inhibitor for Toxoplasma NDH2-I in enzymatic 
assays (Lin et al., 2008) and also inhibits the growth of T. gondii effectively in 
nanomolar concentrations (Saleh et al., 2007). It was interesting to investigate whether 
the conditional knock-out mutants display different sensitivities against HDQ 
treatment. The susceptibility of ∆TgNDH2-I and ∆TgNDH2-II as well as the parental 
parasites to HDQ was compared ± ATc (Fig. 3.9). ∆TgNDH2-II parasites ± ATc 
showed an unchanged sensitivity to HDQ treatment at a final concentration of 10 nM. 
Interestingly, ∆TgNDH2-I parasites were slightly less sensitive to HDQ at 10 nM in 
the presence of ATc (Fig. 3.9A; bar 4). Further analysis on the sensitivity of 
∆TgNDH2-I mutant in response to different HDQ concentrations (Fig. 3.9C) 
confirmed that the depletion of TgNDH2-I is rendering parasites slightly less sensitive 
to HDQ treatment. 
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Figure 3.8 TgNDH2-I and TgNDH2-II depletion mutants show unaltered extracellular 
viability. Intracellular ∆TgNDH2-I and ∆TgNDH2-II, and its parental controls were 
mechanically released by syringe passage, followed by infection (~1×10P5P) on HFF 
confluent monolayer at 0 h and 7 h. Samples were fixed after 24 h post-infection and 
the average numbers of vacuoles were calculated from 4 fields from each slide. 
Extracellular viability was determined by normalization the average numbers of 
vacuoles infected at 7 h with that calculated at 0 h. Results are expressed as means ± 
S.D. from duplicate samples from a representative experiment.  
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Figure 3.9 TgNDH2-I depletion is less sensitive to HDQ. The growth rates of (A) 
∆TgNDH2-I and (B) ∆TgNDH2-II ± ATc treated with HDQ was compared. Knock-
out mutants and its parental controls were grown two rounds ± ATc. Infection (~1×10P5P) 
from each clonal line were inoculated onto HFF confluent monolayer ± ATc exposed 
to HDQ at a final concentration of 10 nM. (C) Comparing the growth rates of 
∆TgNDH2-I ± ATc treated with HDQ at a final concentration of 100 nM, 10 nM, 1 
nM or 0.1 nM. All samples were duplicated, fixed after 24 h, and the average number 
of tachyzoites per vacuole was determined. At least 100 vacuoles were examined for 
each sample. Results were represented as means ± S.D.  
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3.3.2.6 TgNDH2-I or TgNDH2-II Depletion does not affect ∆ψBmB  
 
The impact of TgNDH2s depletion on the mitochondrial membrane potential (∆ψBmB) 
was further investigated based on our previous observation that TgNDH2s inhibition 
collapses ∆ψBmB in T. gondii (Lin et al., 2009). Living ∆TgNDH2-I and ∆TgNDH2-II 
parasites cultivated ± ATc were stained with cationic dye DiOC6(3), and ∆ψBmB of the 
parasites were determined (Fig. 3.10). Our data showed no significant differences of 
∆ψBmB in ∆TgNDH2-I or ∆TgNDH2-II mutants ± ATc, indicating that the depletion of 
either TgNDH2 isoform does not affect parasites in maintaining mitochondrial 
membrane potential. 
 
3.3.2.7 Bradyzoite Differentiation is not influenced in ∆TgNDH2-I and 
∆TgNDH2-II Parasites 
 
Moreover, we tested the influence of TgNDH2-I amd TgNDH2-II depletion on 
bradyzoite differentiation. ∆TgNDH2-I, ∆TgNDH2-II and the parental parasites were 
cultivated ± ATc and bradyzoite differentiation was induced by alkaline pH-shift. The 
differentiation rate of the parasites was compared ± ATc (Fig. 3.11) after 3 days of 
post-infection verified by IFA using bradyzoite-specific anti-BAG1 antibody as a 
differentiation marker (Bohne et al., 1995). The fraction of bradyzoite-positive 
parasites (~5-10%) was similar in ∆TgNDH2-I or ∆TgNDH2-II as well as those in 
parental controls ± ATc. This finding suggests the depletion of either TgNDH2-I or 
TgNDH2-II appearing to have no influence on the bradyzoite differentiation.  
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Figure 3.10 TgNDH2-I and TgNDH2-II depletion mutants show normal ∆ψBmB. ∆ψBmB of 
living (A) ∆TgNDH2-I and (B) ∆TgNDH2-II parasites (± ATc) was compared. 
Intracellular parasites after 24 h post-infection were immediately stained with 
DiOCB6B(3) and the numbers of vacuoles, which possess a positive-∆Ψm were 
determined by fluorescence microscopy from at least 100 vacuoles. Results were 
represented as means ± S.D. from duplicate wells from a representative experiment, 
N=2. 
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Figure 3.11 Depletion of either TgNDH2-I or TgNDH2-II does not affect bradyzoite 
differentiation. The differentiation rate of (A) ∆TgNDH2-I and (B) ∆TgNDH2-II ± 
ATc was compared with parental parasites ± ATc detected by IFA using bradyzoite-
specific anti-BAG1 antibody. Bradyzoite differentiation was induced by alkaline pH-
shift (pH 8.3) for 72 h. Results are expressed as means ± S.D. from duplicate samples 
from a representative experiment, N=2. 
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Discussion 
 
4.1 Both Isoforms of TgNDH2s are Internal Enzymes 
 
 
A comparative genomic study in Apicomplexa has revealed that most of the members 
possess type II NADH dehydrogenases instead of canonical complex I in their 
respiratory chains (Saleh, 2006). Although the reasons for such a preference are 
unclear, it is generally accepted that the crucial role of NDH2 is to maintain NADH 
turnover and ultimately to contribute to the production of ATP (Melo et al., 2004). 
Toxoplasma encodes two isoforms of NDH2 instead of one single gene, as in other 
species such as Plasmodium, Theileria, Cryptosporidium, Eimeria and Babesia. The 
expression of NDH2 is not confined to Apicomplexa, but also described in bacteria, 
plants and fungi, however, it seems exclusively absent in mammals. Due to the 
absence, NDH2 has been considered as a potential drug target (Biagini et al., 2006; 
Saleh et al., 2007; Lin et al., 2008) for the apicomplexan parasites. 
 
Type II NADH dehydrogenase, known as inner mitochondrial-associated membrane 
protein, can be oriented as external or internal version. And it is getting more 
complicated in Toxoplasma owing to the co-existence of two isoforms. The crux of 
understanding the orientations of TgNDH2s is to unveil the precise functions of each 
isoform, which should help to interpret their roles in energy metabolism. More 
specifically, an external orientation implies that only cytosolic NADH, mainly 
produced by glycolytic enzymes, can enter the electron transport chain. In the case of 
an internal enzyme, the reducing equivalents are from the matrix NADH, which is 
mainly contributed from the TCA cycle. At the beginning of this study, the 
orientations of both TgNDH2s were unknown. The experimental data obtained by 
GFP complementation presented in this study for the first time clearly indicate that 
both isoforms of TgNDH2s are more likely to be internal enzymes (Fig. 3.1 and 3.2). 
These data are in contrast with previous suggestions in favor of external orientations 
(Saleh, 2006). However, it is worth to emphasize that earlier predictions are primarily 
based on bioinformatics approaches using phylogenetic analysis among the orthologs 
from apicomplexan parasites and plants. It was shown in Plasmodium that exogenous 
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NAD(P)H, which is presumably impermeable to inner mitochondrial membrane, could 
stimulate electron transport (Fry and Beesley, 1991; Uyemura et al., 2004; Biagini et 
al., 2006). These observations would be in agreement with an external orientation of 
the single PfNDH2. In contrast, the direct evidence provided from T. gondii supports 
the internal enzymes for TgNDH2s, implying that reducing equivalents from matrix 
NADH but not cytosolic NADH are directly utilized by these enzymes. These findings 
are not unexpected and correlate with the earlier identification of a cytosolic 
glyceraldehyde 3-phosphate dehydrogenase in T. gondii (Fleige et al., 2007), 
suggesting the presence of a glycerol phosphate shuttle for the transport of electrons 
from cytosolic NADH to mitochondrial carrier FAD. Taken together, both reducing 
powers from cytosolic and matrix NADH ultimately can enter the oxidative 
phosphorylation pathways. Interestingly, the observations of internal TgNDH2s are in 
line with the earlier study in Yarrowia (Kerscher et al., 2001) demonstrating that in the 
absence of essential complex I, only the internal but not external Yarrowia NDH2 
could rescue the growth defect.  
 
A striking property but also challenging feature of NDH2s is the complexity of 
membrane anchoring. Again, although they are well-known to be membrane-
associated, extensive hydropathy analysis is unable to predict any transmembrane α-
helices (Melo et al., 2004; Fisher et al., 2007). The ongoing question is how these 
enzymes interact with membranes that allows efficient electron transfer 
simultaneously among the hydrophilic NAD(P)H and hydroprobic ubiquinone 
substrates as well as the putative cofactors such as FMN and FAD. Available models 
of membrane anchoring for NDH2s are based on homology prediction and are still a 
matter of controversy (Melo et al., 2004; Fisher et al., 2007; Kerscher et al., 2008). 
But in general, it is believed that the membrane attachment is highly relied on certain 
amphiphathic α-helices (Melo et al., 2004), where hydrophilic headgroups and 
hydroprobic tails are along the α-helices with opposite sites. Such a prediction is also 
proposed in P. falciparum suggesting that a C-terminal amphiphathic α-helice is 
oriented in the membrane lipid bilayer (Fisher et al., 2007). Surprisingly, by using 
GFP complementation, the truncated TgNDH2-IB399B-GFP11 and TgNDH2-IB487B-GFP11 
but not full-length TgNDH2-I-GFP11 are able to reconstitute GFP molecules with 
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TgSCSβ-GFP1-10 line (Fig. 3.2), suggesting that the C-terminus of TgNDH2-I may 
penetrate into the lipid bilayer.  
 
Another pressing point is the identification of quinone-binding sites (ubiquinone in T. 
gondii) for NDH2s following the observations that several compounds targeting at 
quinone-quinol cycle have been considered as potential drug targets (Weinstein et al., 
2004; Eschemann et al., 2005; Yano et al., 2006; Biagini et al., 2008). The elucidation 
of the quinone-binding sites would definitely illuminate invaluable information for 
drug design and for improving drug efficacy. However, the quinone-binding sites are 
unpredictable by primary structures and the majority of the structural models in hand 
have not yet been validated. Nevertheless, there is a consensus that the quinone-
binding regions including the interactive sites of enzymes for hydrophilic quinone 
headgroups and hydrophobic tails, are interfaced at the membrane surface (Melo et al., 
2004; Fisher et al., 2007; Kerscher et al., 2008). For ping-pong mechanisms as 
described for Yarrowia NDH2 and TgNDH2-I (Eschemann et al., 2005; Lin et al., 
2008), a puzzling question raised is how the hydrophilic NADH and hydrophobic 
ubiquinone interact with the enzyme in a common binding pocket. Despite the 
concerns, this kind of interaction is possible since the active site for ubiquinone is 
mainly at the hydrophilic headgroup rather than at the hydrophobic tail that is 
presumably buried at the bilayer (Fisher et al., 2007). However, the exact quinone-
binding sites of each individual NDH2s are variable and further analysis on X-ray 
structures of NDH2s together with valid substrates is necessary to draw a convincing 
model.  
 
4.2 TgNDH2-I is a Drug Target for HDQ 
 
HDQ was first identified as a high affinity inhibitor for Yarrowia type II NADH 
dehydrogenase in enzymatic assays (Eschemann et al., 2005). A subsequent work 
clearly showed that HDQ effectively inhibited the replication rates of T. gondii and P. 
falciparum in vitro with remarkable low ICB50B values in nanomolar (Saleh et al., 2007) 
ranges. By linking these observations, it seems logical to deduce that HDQ may target 
at the same enzymes in Toxoplasma and Plasmodium. However, without experimental 
validation, the drug targets of HDQ in Toxoplasma and Plasmodium remain 
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questionable. Here, enzyme kinetics studies on individual recombinant enzymes 
TgNDH2-I and TgNDH2-II being heterologously expressed in Yarrowia NDH2 
deletion strain provide solid evidence that TgNDH2-I is a drug target of HDQ (Lin et 
al., 2008; see Section 3.1). Further comparing the ICB50B values obtained in recombinant 
enzyme TgNDH2-I and in Yarrowia NDH2 reveals that the ICB50B are within similar 
nanomolar ranges (Eschemann et al., 2005; Lin et al., 2008), identifying HDQ as a 
high affinity inhibitor. A concern is the discrepancy of ICB50B values for TgNDH2-I 
determined in enzyme kinetics (~300 nM) and in vitro (2-4 nM) (also see Discussion 
described in Lin et al., 2008). A key consideration is the efficiency of the interaction 
between the hydrophobic compound HDQ and the enzyme TgNDH2-I. Since NDH2 
requires a hydrophobic environment for its activity (Bjorklof et al., 2000; Melo et al., 
2004; see Section 4.1), HDQ needs to interface along the membrane surface in order 
to contact with NDH2-I, as proposed earlier (Lin et al., 2008). In enzymatic analyses, 
TgNDH2-I recombinant proteins were incubated with HDQ for 5 minutes and the 
inhibition effect was analyzed based on electron transfer activity. For in vitro studies, 
intracellular parasites were incubated with HDQ for 24 hours and the inhibition effect 
was analyzed based on replication rate. By comparison of these two experimental 
settings, the longer incubation of HDQ with the intact enzyme inside the parasites 
achieves a better inhibitory effect. This could partly explain why a much lower ICB50B 
was obtained in in vitro studies.  
 
A noticeable issue about the discrepancy mentioned above is the presence of 
additional drug targets of HDQ, which cannot be completely excluded. These enzymes 
include succinate dehydrogenase, isocitrate dehydrogenase, dihydrooroate 
dehydrogenase, glycerol-3-phosphate dehydrogenase and malate:ubiquinone 
oxidoreductase as well as TgNDH2-II. All of them are upstream of complex III in the 
respiratory chain. Although so far no direct evidence in T. gondii can conclude that the 
captioned enzymes are additional targets of HDQ, it is clear that HDQ targets 
differently from complex III inhibitor atovaquone. HDQ is highly probable interfering 
with the process of ubiquinone reduction based on previous observations from 
substrate supplementation experiments (Lin et al. 2009; see Section 3.2). Results 
showed that HDQ-mediated but not complex III inhibitor atovaquone-mediated 
collapse of ∆ψBmB was partly stabilized with excess substrates for the other 
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dehydrogenases, indicating that TgNDH2 inhibition is partly rescued by additional 
electrons to compensate the ubiquinol pool (Lin et al., 2009; see Section 3.2). A more 
recent study in Plasmodium has demonstrated that diphenylene iodonium chloride 
(DPI) and HDQ inhibited recombinant PfDHOD instead of PfNDH2 using E. coli for 
heterologous expression (Dong et al., 2009). For DPI, this finding is slightly 
unexpected since previous work (Biagini et al., 2006) demonstrated that DPI 
decreased the activity of P. falciparum NDH2, even though a very high micromolar 
dosage was applied. However, several hiding points not well-mentioned on both 
studies need to take into consideration such as the purities of PfNDH2 described in 
both assay systems, the stabilities of the PfNDH2 in the absence of membrane 
environment (Dong et al., 2009) that is important for NDH2 activity (Bjorklof et al., 
2000), and the specificity of DPI to PfNDH2. Without narrowing the disparities of 
these noticeable points, further evidence is required to make a conclusive statement. 
To follow up the observation of HDQ targeting at PfDHOD instead of PfNDH2, one 
may over-simplify that HDQ may also target at DHOD in Toxoplasma. Up to now, it 
is unlikely to support this claim unless direct evidence from functional assays on 
TgDHOD reveals the specificity of HDQ in T. gondii. Moreover, it should be noted 
that the importance of mitochondrial enzymes in Plasmodium and Toxoplasma are 
different (van Dooren et al., 2006; Painter et al., 2007; Seeber et al., 2008). By simply 
shuttling the observations of Plasmodium and Toxoplasma one another can distort the 
understanding of the complete stories of energy metabolism in each parasite.    
 
Despite, there were recently debates about the validity of NDH2s as a drug target, 
especially in Plasmodium (Fisher et al., 2007; Vaidya et al., 2007). Previous findings 
(Biagini et al., 2006) demonstrated that low affinity inhibitors for PfNDH2 strongly 
decreased the activity of the Plasmodium ortholog, followed by the collapse of ∆ψBmB 
and finally lead to parasite death, suggesting an essential role of PfNDH2. On the 
contrary, another study showed that over-expression of type 1 S. cerevisiae ubiquinol 
independent DHOD in P.  falciparum made parasites completely resistant to the 
complex III inhibitor atovaquone (Painter et al., 2007). This finding argues the 
importance of PfNDH2 in the respiratory chain (Biagini et al, 2006), suggesting that 
the function of P. falciparum complex III is to regenerate the electron acceptor for the 
endogenous DHOD, which is the fourth enzyme of pyrimidine biosynthetic pathway. 
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However, it is still early to conclude that NDH2 and other mitochondrial 
dehydrogenases are non-essential (Fisher et al., 2008). To give an example, in the 
absence of essential complex I activity in Yarrowia, NDH2 activity in the 
mitochondrial matrix is essential for survival (Kerscher et al., 2001). Discussion is still 
ongoing, but it is pertinent to point out that even within the phylum Apicomplexa, the 
importance of mitochondrial enzymes including NDH2 to a large extent can be 
species-dependent, just considering that ATP pools contributed from oxidative 
phosphorylation for Plasmodium in intraerythrocytic stage compared with Toxoplasma 
in parasitophorous vacuoles are very different (Seeber et al., 2008). 
 
Now, more than ever, DHOD has drawn the most attention among the mitochondrial 
dehydrogenases (Gutteridge et al., 1979; Vaidya et al., 2007) in Apicomplexa. 
Preliminary findings (Naujoks, 2008; Sternisek, 2009) in Toxoplasma demonstrated 
that a uracil phosphoribosyltransferase (UPRT)-deficient mutant was more sensitive to 
HDQ compared with wild-type RH strain in long-term treatments as defined by an 
exposure with HDQ for 48 h up to 96 h, suggesting that HDQ may target pyrimidine 
de novo biosynthetic pathway. Although these emerging data seem interesting, it is not 
well-supported. Uracil supplementation experiments showed that it did not lead to an 
increased growth rate (Lin et al, 2009; Sternisek, 2009), indicating that HDQ growth 
inhibition is unlikely targeting at pyrimidine starvation. Uracil can rescue parasites 
deficient in de novo pyrimidine biosynthesis as shown in earlier study (Fox and Bzik, 
2000) since it is converted by the parasitic UPRT to 5’-monophosphate (UMP), and 
UMP is further processed into nucleotides. As a rule of openness, it cannot be 
completely excluded that this pathway is also targeted by HDQ. However, previous 
postulation that DHOD is a possible target for HDQ is still unclear since no evidence 
has been provided. But at a circumstance, it is understandable since DHOD is the 
fourth enzyme in de novo pyrimidine biosynthetic pathway, which links to the 
respiratory chain concerning its role in ubiquinone recycling (Fox and Bzik, 2000). 
Nevertheless, much more works need to be done to unveil the underlying mechanism 
involved. However, without reliable data mentioning the equivalent powers actually 
contributed from other dehydrogenases and more critically the efficiency of the 
electrons from other dehydrogenases indeed fed into ETC, it may be too early to 
overestimate the contribution of electrons from other dehydrogenases and/or 
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underestimate the importance of TgNDH2s in the respiratory chain. Nevertheless, it is 
still a question mark about the putative drug targets for HDQ. Definitive evidence that 
no other targets contribute to the HDQ-mediated growth inhibition will require an 
analysis of resistant determinants, as described in detail previously (McFadden et al., 
2000). 
 
4.3 TgNDH2-I and TgNDH-2-II are non-essential for Replication Growth 
 
It is becoming obvious that oxidation phosphorylation in T. gondii plays a pivotal role 
in energy production (Vercesi et al., 1998; Lin et al., 2009). The importance of this 
process relies on electron transport system exerted on a panel of mitochondrial 
enzyme complexes. Of interest, this study specifically explores the functional roles of 
mitochondrial TgNDH2s, which have been shown as promising drug targets (Saleh et 
al., 2007; Lin et al., 2008, 2009). NADH dehydrogenases in all aerobic organisms are 
known as the main entry site for reducing equivalents from the metabolism to the 
respiratory chain. However, the question about the essence of TgNDH2s in 
Toxoplasma has not yet been answered. To assess this point, two conditional knock-
out mutants TgNDH2-I and TgNDH2-II were firstly generated based on homologous 
recombination by using recombineered cosmids (Fig 3.5; Lee et al., 2001). 
Unexpectedly, phenotypic analyses of these two TgNDH2-I and TgNDH2-II depletion 
mutants showed that the growth rates of both isoforms were identical to parental 
parasites, indicating that either TgNDH2-I or TgNDH2-II is non-essential for 
intracellular replication in tachyzoite stage (Fig. 3.6).  
 
Furthermore, phenotypic studies including extracellular viability (Fig. 3.8), ∆ψBmB (Fig. 
3.10) and bradyzoite differentiation (Fig. 3.11) on each depletion mutant and their 
parental strains did not reveal any differences, speculating that the endogenous 
isoform may be redundant and can compensate the loss of the second isoform to 
maintain their metabolic roles. Regarding to this suggestion, one criterion is that both 
isoforms need to be oriented with the same side in order to transfer electrons from 
either cytosolic or mitochondrial NADH. Noticeably, results from split GFP 
complementation provides clear evidence that both isoforms are oriented as internal 
enzymes with their active sites facing towards the mitochondrial matrix, which fulfils 
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this crucial criterion. Although it cannot direct prove that a redundancy indeed exists 
between these two isoforms, it indicates that the suggested scenario is appropriate for 
TgNDH2s. In an attempt to test this hypothesis, comparisons of the transcript levels of 
endogenous isoforms in each knock-out mutant were examined by quantitative RT-
PCR. However, no significant up-regulation of each endogenous TgNDH2 isoforms 
was observed in knock-out mutants, which indirectly indicates that the demand of 
endogenous TgNDH2 transcript levels (Fig. 3.7) seems unchanged. Whether a 
functional redundancy is seen between these two isoforms or not seems impossible to 
be predicted by sequence analyses. Very little hints are derived from bioinformatics 
studies, which reveal that both isoforms are nearly 40% amino acid identical and can 
be originated from a gene duplication event (Saleh, 2006), similar to what was 
proposed in S. cerevisiae (Kerscher, 2000). Remarkably, T. gondii is the only 
organism in Apicomplexa possessing two isoforms of NDH2. Nevertheless, a detailed 
phenotypic analysis on the double knock-out mutant for TgNDH2s in the near future is 
the solution to answer this interesting question.  
 
So far, the only phenotypic difference is the detection of a slightly lower susceptibility 
to HDQ in the conditional TgNDH2-I knock-out mutant in the presence of ATc (Fig. 
3.9). The decreased sensitivity to HDQ in conditional TgNDH2-I knock-out mutant 
was consistently observed in a varied range of HDQ concentrations in the presence of 
ATc compared to those, which were cultivated in the absence of ATc. However, it 
needs to be stressed that the decreased sensitivity using the average number of 
parasites per parasitophorous vacuole for comparisons is only a slight difference. This 
indicates that, even without TgNDH2-I activity, HDQ is still able to inhibit the 
intracellular replication, suggesting HDQ may have additional targets. At this stage, 
these additional targets are still unknown, however as a logical speculation, TgNDH2-
II might be the possible target due to the same internal orientation and similar function. 
Both enzymes were able to transfer electrons from NADH to DBQ as demonstrated in 
enzymatic studies (Lin et al., 2008). Meanwhile, an additional interpretation for the 
decreased sensitivity would imply that the endogenous TgNDH2-II and also additional 
other possible drug targets probably possess a lower affinity for HDQ. In the near 
future, one feasible study is to compare the affinity of TgNDH2-I and TgNDH2-II 
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enzyme activities to HDQ using Toxoplamsa lysates isolated from knock-out mutant, 
parental and wild-type parasites. 
 
Using conditional knock-out mutants is an important approach to validate essential 
genes (Meissner et al, 2002; Mital et al., 2005). One major technical concern is how 
effective the additional copy of exogenous gene can be repressed in the tetracycline-
regulatable expression system in the knock-out mutant. Although the inducible system 
is functional in both TgNDH2-I and TgNDH2-II mutants as shown by the suppression 
of exogenous copies in the presence of ATc (Fig. 3.9), it is very difficult to rule out 
that the residual transcript levels are sufficient to complement the loss of the knock-
out genes. One possible solution to deal with this technical issue is to generate clean 
TgNDH2-I and TgNDH2-II knock-out mutants and compare the phenotypes.   
 
4.4. A proposed Model explaining the Importance of TgNDH2s in T. gondii 
 
This study explores the importance of TgNDH2s in the energy metabolism of T. 
gondii. Here for the first time, direct evidence from split GFP complementation has 
revealed that both isoforms are internal enzymes (Fig. 3.1 and 3.2). It is this becoming 
clear that these two enzymes utilize the reducing powers from matrix NADH but not 
from cytosolic NADH and the oxidized electrons are ultimately fed into the 
respiratory chain. In addition, this study strongly suggests that T. gondii possesses a 
conventional-like ATPase as supported by the localization of a membrane associated-
ATPase-FB1B β subunit (Lin et al., 2009), which is in contrast with the proposed soluble 
ATPase FB1B in P. falciparum (Painter et al., 2007). Importantly, the identification of 
this typical-like ATPase in T. gondii reflects that oxidative phosphorylation may play 
a critical role in ATP production. Remarkably, a fast collapse of mitochondrial inner-
membrane potential within minutes followed by a serious depletion of parasitic ATP 
level was observed with HDQ treatment (Lin et al., 2009; see below). This directly 
reveals the physiological impact of TgNDH2 inhibition on mitochondrial functions – 
type II NADH dehydrogenases are indispensably important for oxidation 
phosphorylation in the replicative tachyzoite stage. Further investigation on the ∆ψBm Bin 
bradyzoites revealed a significant lower frequency of ∆ψBmB-positiveB Bparasites 
suggesting that oxidation phosphorylation in the bradyzoite stage may be less 
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important compared to tachyzoites. Collectively, these important findings have 
advanced the understanding of the complete picture of the electron transport chain in T. 
gondii (Fig. 4.1). Overall, a model depicting the importance of type II NADH 
dehydrogenases T. gondii is proposed (Fig. 4.1). Internal enzymes TgNDH2-I and 
TgNDH2-II are oxidizing electrons from matrix NADH. The donated electrons 
including from other dehydrogenases are accepted by ubiquinone to give a reduced 
form ubiquinol. Electrons then are donated from ubiquinol to complex III, further 
passed to cytochrome c and complex IV. The energy released from electron transfer 
steps are used by complex III and IV to pump protons from matrix to intermembrane 
space and generated an electrochemical gradient. Subsequently ATP is produced by 
the action of ATPase using the potential energy from the proton gradient.  
 
Type II NADH dehydrogenases in T. gondii have been considered as promising drug 
targets due to the absence in mammalian cells (Saleh et al., 2007). The enzymatic 
analyses presented here have provided clear evidence that TgNDH2-I is indeed a drug 
target for HDQ (Lin et al., 2008). The quinolone-like compound HDQ was first 
identified as a high affinity inhibitor for Yarrowia NDH2. Strikingly, an impressive 
ICB50B for TgNDH2-I is determined in nanomolar ranges, implying that HDQ is a high 
affinity inhibitor for this enzyme. Bisubstrate kinetics analysis suggests a ping-pong 
mechanism for TgNDH2-I enzyme activity. Inhibition kinetics analysis indicates that 
hydrophobic HDQ is both competitive and non-competitive inhibitor for hydrophobic 
ubiquinone in a ping-pong mechanism. Further comparisons on the mode of action of 
HDQ with complex III inhibitor atovaquone in substrate supplementation experiments 
(Lin et al., 2009) in intracellular parasites suggests that HDQ is targeting at the 
ubiquinone reduction level, which is different from atovaquone. Taken together, the 
impact of TgNDH2s inhibition in the respiratory chain is stepwise described (Fig. 4.1). 
First, the hydrophobic compound HDQ is reaching at the membrane interface, where it 
can interact with TgNDH2-I. As a ping-pong mechanism for TgNDH2-I (Lin et al., 
2008) activity, HDQ interferes with TgNDH2-I activity in several ways. HDQ can 
affect catalytic activity of TgNDH2-I by binding directly to the enzyme (non-
competitive for NADH and ubiquinone) and it can compete with ubiquinone for the 
binding site as a competitive inhibitor. As a result of HDQ inhibition, ubiquinol 
turnover is reduced, eventually causing a collapse of ∆ψBm Band depletion of ATP level. 
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Figure 4.1 A proposed model depicting the importance of type II NADH 
dehydrogenases in the energy metabolism of T. gondii (A) Internal enzymes 
TgNDH2-I and TgNDH2-II transfer electrons from matrix NADH entering the 
respiratory chain. ATP is synthesised by the action of a conventional-like ATPase in T. 
gondii. (B) Physiological consequences of type II NADH dehydrogenases inhibition 
by HDQ. It comprises following steps: 1. Partition of hydrophobic quinone-like 
compound HDQ at membrane interface; 2. Ping-pong mechanism of TgNDH2-I 
electron transfer activity; 3. HDQ targeting at TgNDH2-I; 4. Collapse of ∆ψBmB; and 5. 
ATP depletion. G3PDH, glycerol-3-phosphate dehydrogenase; DHAP, dihydroxyacetone phosphate; 
G-3P, glycerol-3-phosphate; NDH2, type II NADH dehydrogenase; MDH, malate:ubiquinone 
oxidoreductase; OAA, oxaloacetate; DHOD, dihydroorotate dehydrogenase; Cyt c, cytochrome c; CoQ: 
ubiquinone; CoQHB2B, ubiquinol.      
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Summary 
 
The single subunit mitochondrial type II NADH dehydrogenases (NDH2s) in 
apicomplexan parasites have been considered as potential drug targets due to the 
absence in mammalian cells. Toxoplasma gondii encodes two isoforms of NDH2s, 
TgNDH2-I and TgNDH2-II, whose functions are not known. Therefore, this study is 
explicitly focusing on drug target validation of these enzymes as well as revealing 
their specific roles in both mitochondrial functions and energy metabolism in T. gondii. 
 
The validity of TgNDH2s as putative targets was firstly addressed in this study. 
Previously, the quinolone-like compound 1-hydroxy-2-alkyl-4(1)quinolone (HDQ), 
known as a high affinity inhibitor for Yarrowia lipolytica NDH2, has been shown to 
effectively inhibit the replication of T. gondii. To obtain biochemical evidence that 
TgNDH2s are the targets for HDQ, both TgNDH2 isoforms were heterologously 
expressed in a Yarrowia NDH2 deletion strain. TgNDH2-I was able to display 
oxidoreductase activities by using NADH and n-decylubiquinone as substrates. 
Additionally, TgNDH2-I could rescue the loss of complex I activity in Yarrowia, 
indicating that TgNDH2-I is expressed as an active enzyme. Furthermore, TgNDH2-I 
activity was effectively inhibited by HDQ with an ICB50B at nanomolar concentration. 
Steady-state kinetics analyses for TgNDH2-I are in accordance with a ping-pong 
mechanism. Moreover, the mode of inhibition of HDQ on TgNDH2-I revealed that 
HDQ is a non-competitive inhibitor for NADH. Collectively, these biochemical data 
provide direct evidence that TgNDH2-I is a target enzyme of HDQ in T. gondii.  
 
Having validated TgNDH2 activity as a target of HDQ, the physiological impact of 
HDQ activity on mitochondrial functions was examined next. Intracellular parasites 
exposed to HDQ displayed a significant collapse of the mitochondrial membrane 
potential (∆ψBmB). Strikingly, ∆ψBm Bin living parasites was depolarized within minutes, as 
recorded by time-lapse microscopy. The effect was diminished by adding substrates 
for mitochondrial dehydrogenases located downstream in the respiratory chain, which 
is in agreement with a specific inhibition of TgNDH2 activity by HDQ. Further 
experiments demonstrated that ∆ψBmB in the presence of HDQ was stabilized with the 
FB0B-ATPase inhibitor oligomycin, indicating that T. gondii is likely to possess a 
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conventional-like mitochondrial FB0BFB1B-ATPase. Additional subcellular localization of a 
membrane-associated FB1B-ATPase β subunit strongly supports this location, which is 
different to the location previously suggested to Plasmodium as a soluble matrix 
protein. Moreover, the collapse of ∆ψBm Bmediated by HDQ is followed by a significant 
depletion of the intracellular parasitic ATP level. Taken together, these findings 
indicate that HDQ is an effective inhibitor of oxidative phosphorylation in tachyzoites. 
Interestingly, the percentage of ∆ψBmB-positiveB Bbradyzoites is significantly lower as 
compared to tachyzoites, implying that the importance of oxidative phosphorylation 
varies in these two stages.   
 
Moreover, the integration of TgNDH2s in the parasitic energy metabolism was 
explored. A split GFP complementation approach was used in order to determine 
whether the active sites of the TgNDH2 isoforms are facing to the mitochondrial 
matrix or to the intermembrane space. A parasite line expressing a matrix-localized 
succinyl-CoA synthetase beta subunit (TgSCSβ)-GFP1-10 fusion protein was 
generated and transfected with TgNDH2-I-GFP11 or TgNDH2-II-GFP11 fusion 
constructs. Full-length constructs of TgNDH2-II and truncated versions of TgNDH2-I 
were able to reconstitute GFP fluorescence, suggesting an internal, matrix-oriented 
localization of both enzymes. This indicates that both enzymes are specifically using 
NADH contributed from the matrix but not from the cytosol. Further investigations on 
the specific functional roles of TgNDH2s were focused on phenotypic analyses of 
conditional TgNDH2-I and TgNDH2-II depletion mutants. Unexpectedly, the 
phenotypic studies on these mutants showed that either TgNDH2-I or TgNDH2II is 
non-essential for replication, suggesting that TgNDH2s may be highly functional 
redundant and in turn complement each other.  
 
The mode of action of HDQ together with the biochemical and molecular findings on 
TgNDH2s presented here may contribute to the ongoing strategic drug development to 
combat the emerging drug resistance of apicomplexan parasites. 
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